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ABSTRACT 
 
 
Characterization of A2:  The Lysis Protein of ssRNA Phage Q. (August 2012) 
Catrina Anne Reed, A.S., Cisco Junior College; 
B.S., McMurry University 
Chair of Advisory Committee: Dr. Ryland F. Young 
 
 
Lysis in cells infected with the ssRNA phage Q is effected by the A2 protein.  It 
was previously shown that a single copy of A2 assembled on the surface of the Q virion 
inhibited the activity of MurA, which catalyzes the first committed step of murein 
biosynthesis.  This led to a model for lysis timing in which A2 is not active as a MurA 
inhibitor until assembled into virion particles.  Here we report that MurA inactivates 
purified Q particles.  Moreover, over-expression of MurA does not inactivate particles 
during the Q infection cycle; thus, casting doubt on the notion that completed virions 
could be the lytic agent in vivo and also that the MurA-virion interaction does not occur 
in the infected cell.  Furthermore, RNA released from particles was found to protect 
virions from inactivation by MurA in vitro, suggesting that Q RNA might serve as the 
protective element during the infection cycle.  Comparison of A2 accumulation between 
Q and Q por mutants, which are Q A2 mutants with a shorter infection cycle and 
reduced burst size, reveals that a delicate balance between assembled and unassembled 
A2 levels regulates lysis timing.  A new model is proposed in which “free”, unassembled 
iv 
 
A2 inhibits MurA.  From in vitro binding studies and genetic analyses it was determined 
that A2 binds MurA in a closed conformation with UDP-N-acetylglucosamine bound.    
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
Mode of Phage Virion Release 
Studies of the bacteriophage (phage) infection cycle have been important for our 
understanding of gene replication, expression, and regulation. One fundamental question 
of this infection cycle that has received less attention is:  How do newly formed virion 
particles escape their host cell?  Two basic strategies have evolved for this purpose: (i) a 
nonlethal form of secretion is employed by filamentous phages in which a secretion 
apparatus is encoded for continuous extrusion of progeny phage from the host cell and 
(ii) a lytic method that results in host cell rupture (lysis) due to physical degradation of 
the bacterial cell wall (murein) or alternatively, inhibition of cell wall 
biosynthesis/turnover (15). 
 
dsDNA phage lysis 
Interestingly, the means by which lytic phages lyse a host cell correlates with the 
size of their genome.  Phages with large genomes encode a muralytic enzyme that 
degrades the cell wall, along with other proteins to regulate its function and, in the case 
of Gram-negative bacteria, to disrupt the outer membrane (174) (FIG. 1).  Lysis and the 
____________
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FIG. 1.  The  lysis paradigm.  Lysis proteins accumulate in the membranes 
and cytoplasm of the cellular envelope of a Gram-negative host:  S105 (blue, 
IM), R (green, Cyt), Rz (purple, IM), and Rz1 (orange, OM).  S105 
accumulates and oligomerizes in the inner membrane (IM) until an allele 
specific triggering time when the proton motive force collapses and triggers a 
large hole formation.  This triggering event releases R molecules that were 
accumulating in the cytoplasm (Cyt) into the periplasmic space (Peri) to 
degrade the cell wall (CW).  The last event in lysis is disruption of the outer 
membrane (OM) by the spanin-complex (Rz-Rz1). 
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termination of the infection cycle is an explicitly programmed event for complex phages 
with double-stranded nucleic acids.  For Caudovirales, at least two and as many as five 
proteins are required for efficient, temporally-regulated lysis (174).  The minimal set is 
comprised of a holin and an endolysin.  The former is a small integral membrane protein 
that controls the timing of lysis by permeabilizing the cytoplasmic membrane in a 
temporally-regulated manner.  This allows release of the endolysin into the periplasmic 
space to attack the peptidoglycan.  Holins are genetically malleable, allowing rapid 
mutational adjustment of the length of the infection cycle to fit changing environmental 
scenarios. 
In terms of membrane topology, there are three classes of holins that have been 
experimentally characterized (FIG. 2) (174):  (i) Class I, proteins with three 
transmembrane domains (TMD) and an N-out, C-in topology.  Representatives of this 
class include  S and P2 Y.  (ii) Class II proteins have two TMDs, with both N and C 
termini disposed in the cytoplasm.  The prototypical protein from this class is S21 from 
phage 21.  (iii) Finally, class III contains protein with a single TMD and a large 
periplasmic domain that adopts an N-in and C-out topology.  This class is represented by 
the 216 amino acid (aa) T protein of phage T4.  Class I and II holins are extremely 
diverse, with many unrelated gene families.  Class III is uniquely populated by T and its 
homologs, mostly in T4-like phages.   
All three holin classes are regulated by different mechanisms.  The prototypical 
class I holin gene,  S, is a reading frame of 107 codons encoding two gene products,  
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FIG. 2.  Holin topologies.  Three general classes of holins have been 
experimentally determined.  Class I holins, such as  S, have 3 transmembrane 
domains (TMD) with N-out, C-in topology.  Class II holins like S21 from 
phage 21, have 2 TMDs with N-in, C-in topology.  The third class of holins 
have a single TMD with the N-terminus inside and a large C-terminal domain 
in the periplasm. 
5 
 
 
S107 and S105, based on translational initiations at either codon 1 or codon 3 (123).  
The holin, S105, accumulates harmlessly in the membrane until suddenly “triggering” to 
form large holes of a 100 nm-1 m scale (34).  The precise molecular basis of holin 
triggering is unknown, but it involves massive oligomerization, a collapse of the proton 
motive force (PMF), and a reorganization of the holin into a large hole of micron scale 
diameter (34, 174, 175).  The massive hole allows non-specific escape of the phage 
endolysin from the cytoplasm, leading to immediate degradation of the peptidoglycan 
(159).  The S107 product is designated as an antiholin, in that it binds to S105 and 
inhibits its oligomerization (19).  The operational difference between S107 and S105 is 
that there is a lysine residue at position 2; the additional positive charge prevents S107 
from assuming the N-out, C-in topology.   
The S21 protein from phage 21 is the only class II holin that has been 
characterized experimentally (174).  Unlike S105, when S21 triggers, it forms small 
heptameric holes, with channels estimated at < 2 nm diameter (114).  For this reason, S21 
has been designated as a “pinholin”.  Because these holes, designated as “pinholes” are 
so small, endolysins cannot pass through them to attack the cell wall (120).  Thus 
pinholins require that the endolysin be secreted by the host sec system.  These special 
endolysins, designated as SAR endolysins, accumulate in the periplasm in an inactive, 
membrane-tethered form (172, 174).  Upon depolarization of the membrane by holin 
triggering, the SAR endolysins release from the bilayer, refold into an active 
conformation, and attack the peptidoglycan.   Like  S, the S21 gene produces both a 
holin and antiholin form based on alternate translational starts (5).   
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Some phages, like the classical phage T7, encode class II holins but also make 
canonical endolysins, lacking signal sequences.   These class II holins must thus make 
large holes like  and other class I holins, but this has not been experimentally addressed 
(174). 
Both class I holins and the class II pinholins do not appear to be regulated in a 
real time sense; that is, a particular allele of either type of holin will trigger lysis at an 
allele-specific time.  Class III holins, such as T4 T, share the ability to make large holes 
like those made by the  holin (34, 174).  However, T and its homologs have the ability 
to be actively regulated by environmental information.  This process, known as lysis 
inhibition (LIN), is regulated by the antiholin, RI in T4 infections, which is secreted into 
the periplasmic space (107, 153).  RI complexes with the holin, T, and prevents holin 
oligomerization (107, 153).  RI is susceptible to proteolytic cleavage with a half-life of ~ 
2 minutes (152); therefore, continuous secretion of RI is needed to maintain the LIN 
state.  An unknown signal from superinfecting phages assists in stabilizing RI and 
extending the half-life nearly tenfold.           
The final step in virion release is disruption of the OM of the Gram-negative host 
cell.  This is accomplished in  infections by production of a spanin complex, Rz and 
Rz1, which spans the width of the periplasmic space (17).  It has been proposed that 
upon removal of the murein, by the endolysin, a conformational change of the spanin 
complex induces inner and outer membrane fusion and release of progeny virions.   
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ssDNA/ssRNA phage lysis 
There are three types of small phages with single-strand nucleic acids and 
genome sizes of ~5 kb or less, all of which infect Gram-negative bacteria: the 
Alloleviviridae (ssRNA; prototype Q), Leviviridae (ssRNA; prototype MS2), and 
Microviridae (ssDNA; prototype X174) (FIG. 3).  In contrast to phages with large 
genomes, these three types of simple phages effect lysis by expression of a single gene 
without muralytic activity (15).  Of these “single gene” lysis systems, two are known to 
cause lysis by inhibition of an essential enzyme in the murein precursor pathway:  Q A2 
inhibits MurA (16) and X174 E inhibits MraY (13).  In both cases, lysis primarily 
occurs when the host cell attempts to septate in the absence of murein synthesis.  The 
third, MS2 L, effects lysis by an unknown mechanism that does not affect murein 
synthesis nor require cell division.    
The ssRNA phages are similar in their virion structure and mechanism of 
infection but are distinguished based on their 5’ and 3’-end RNA secondary and tertiary 
structures, serological properties, and lysis proteins (156).  MS2 and Q have a similar 
core genomic structure, with three genes: 5’-assembly-coat-replicase-3’ (56, 67) (FIG. 
3).  The assembly protein in Q (A2) serves as the lysis protein for this system; however, 
MS2 has a fourth gene, L, dedicated to lysis, which lies in an alternative reading frame 
that overlaps the 3’-end of the coat gene and the 5’-end of the replicase gene.     
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FIG. 3.  Genomic maps of phages with single lysis gene products.  
Microviridae phages have a circular genome of ssDNA (depicted as linear).  
Alloleviridae and Leviviridae phages have genomes comprised of ssRNA.  Q-
like phages produce A1 protein from read-through of the coat gene.  Lysis 
proteins are highlighted. 
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Little is known in these systems about lysis regulation at the post-translational 
level.  In X174 infections, E appears to be made in sufficient quantities to inhibit all the 
MraY in the cell soon after infection (14).  Production of sufficient virions is achieved 
only because there is a significant lag time between the halt in cell wall biosynthesis and 
the average time before the host cell attempts to septate.  A host cis-trans peptidylprolyl 
isomerase, SlyD, is required for stabilization of the E protein and may be key to lytic 
regulation (12).  The Q lysis system is unique in that the lysis protein, A2, has other 
roles essential to maturation protein functions, such as morphogenesis, adsorption to the 
host, and penetration of the genomic RNA to the cytoplasm.  At the very least, the other 
functions assigned to A2 require binding to Q RNA, the phage particle, and the host F-
pilus, thus providing an assortment of potential regulatory modes in the infected cell.   
 
The Q Life Cycle 
Q was isolated by Watanabe in 1964 (71, 162) three years after the first RNA 
phage was discovered (95).  Much of what is known about the Q system comes from 
the studies of the related Levivirus phages.  Q is a ssRNA bacteriophage whose 4.2kb 
genome contains three cistrons that encode four proteins:  maturation or A2, coat, read-
through coat or A1 and replicase (FIG. 3).  The 5’gene is called A in MS2 and A2 in Q.  
It encodes a ~ 48 kDa protein that is present in a single copy on the virion, has multiple 
functions and is required for infectivity.  In both Q and MS2, it is also referred to as 
“maturation protein” or “assembly protein” depending on the context.  The maturation 
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protein binds a single RNA genome and is assembled with approximately 165 copies of 
the coat protein, ~ 15 copies of the read-through coat protein and a single copy of A2 
(156) mounted on the surface of the virion particle.  A1 is the result of low level read-
through of the UGA termination codon of coat, resulting in insertion of a tryptophan 
residue and extension of  the reading frame by 196 residues (84).  Despite the low level 
of expression, estimated at < 15 copies per progeny virion, A1 is required for infectivity 
(42, 57, 84, 165).  The replicase gene product is an RNA-dependent, RNA polymerase, 
necessary for synthesis of new viral RNA.  Replicase associates with several host 
proteins:  EF-Ts, EF-Tu, S1 to form the replicase holoenzyme (71), and in the case of 
Q an additional host protein, Hfq (HF-I), is required for synthesis from the positive 
strand (25, 45, 103).  
 
Adsorption of ssRNA phage and injection of viral RNA  
RNA phages require a conjugative pilus for infection.  The best-studied RNA 
phages are those that bind to the F sex factor pilus, the MS2-like Leviviridae and the Q-
like Alloleviviridae.  Adsorption of virion particles to filtered F-pili was observed with 
the MS2-like f2 phage but not an f2 mutant that lacked the A protein (93), which 
suggests that the maturation protein is located on the surface of the particle and serves a 
role as recognition protein for the F-pilus.  Association of the particle to purified pili was 
also shown to be dependent on the presence of a divalent cation (155), and this 
dependence has also been reported for infection of bacteria by phage (115).  
11 
 
 
Visualization of phage and pili complexes showed that RNA phage adsorb along the side 
of the pilus unlike filamentous phage that adsorb to the tip (26).  Moreover, mutant 
forms of the major F-pilus subunit, TraA, with increased overall positive charge were 
shown to reduce the ability of RNA phage to adsorb (46).   
Adsorption of R17 virion particles, a MS2-like phage, to the F-pilus is 
heterogeneous (86, 118) due to a mixture of infectious and noninfectious particles.  
About 10% of a population, thought to be deficient in the maturation protein, does not 
adsorb to the pilus.  Another 10% of the phage efficiently bind the pilus and are highly 
infective.  The remaining 80% of phage particles weakly adsorb to the F-pilus and are 
not infective.  A possible explanation for the difference between the infectious and 
noninfectious particles that adsorb to the pilus could be from an improper orientation of 
the maturation protein on the surface of the particle such that particles are able to weakly 
bind the F-pilus but not elicit ejection of the viral RNA.    
It was discovered that an f2 phage titer, defined as the plaque-forming-units 
(PFU) per ml, decreases in the presence of cell-free F-pili.  This particle association with 
purified F-pili was thought to “inactivate” particles (155).  However, subjecting the pili-
phage mixture to shearing in a blender released viable particles.  Also, addition of RNase 
to the reaction did not cause dissociation from the purified pili as in the case with cell-
associated pili suggesting that ejection of the RNA from the capsid is not occurring.  
Therefore, the authors proposed that particles are able to reversibly bind to cell-free 
pilin, and that an additional step beyond physical association of the maturation protein to 
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the F-pilus is needed for RNA ejection from the capsid.  The ejection step is believed to 
be energy dependent since cell-associated pili are required for ejection of the RNA from 
the capsid and a drop in cellular nucleotide triphosphates is also observed with infection 
(116). 
Upon ejection from the capsid, the viral RNA is piloted into the host cell with the 
assistance of the maturation protein (83, 85).  Wong and Paranchych proposed that the 
ejection is polar with ejection of the 3’-end first.  The authors chemically treated R17 
phage particles with ascorbate and Cu2+, which fragmented the RNA, and added the 
treated phage particles to a bacterial culture.  Analysis of the particles after infection 
revealed a simultaneous loss of the A protein and the 3’-end fragment (170) suggesting 
that the A protein and the 3’-end of the viral RNA are ejected from the capsid first.   
Injection of the viral RNA proceeds rapidly in the first 5 minutes of an infection 
after which the penetration slows down for the rest of the infection cycle.  This initial 
injection stage or eclipse period correlates with a reduction in the amount of cellular 
nucleoside triphosphates (32, 119).  Krahn and colleagues had found that only 30-35 
phage RNA equivalents can penetrate a single cell (85, 116); however, Paranchych and 
colleagues determined that as much as 250 viral RNA molecules can be transferred to a 
bacterial host during a single eclipse period with high inputs of infective phage particles 
(116). The authors observed that with an input multiplicity of infectious (MOI) phage 
particles ≤ 10 per cell, nearly all the RNA is able to penetrate, but if input MOI was 
higher than 10 phage per cell, large increases in infectious phage particles are required to 
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achieve small increases in RNA penetration.  This suggests that the bacterium has 
developed a mechanism to limit the amount of RNA that penetrates the cell.    
The maturation protein pilots the viral RNA into the host cell and in the process 
is thought to be cleaved, based on experiments with radiolabelled particles (83, 85).  
Krahn and colleagues found that labeled A protein from the MS2-like phage, R17, is 
injected into the bacteria at a 1:1 molar ratio of A protein to viral RNA (85).  Analysis of 
the protein from the infected cells revealed three distinct peaks which correspond to 39, 
24 and 15 kDa; the sum of the latter two protein masses matches that of the full length A 
protein (39 kDa), so the authors proposed that the maturation protein was cleaved upon 
injection into the host cell.  Kozak and Nathans also reported two peaks that appear to be 
of similar size to the protein cleavage products seen by Krahn and colleagues, with the 
smaller of the two running at about the same molecular weight as coat (83, 85); however, 
the authors proposed that the peaks could be degradation products from experimental 
manipulation prior to sample analysis.  The cleavage of the maturation protein was 
thought to be an attractive possibility for signaling of RNA ejection from the particles 
(119).  A different conclusion was reached by Zinder and Cooper.  The authors infected 
a nonsuppressor strain with an f2 mutant containing a nonsense mutation in the A gene 
(83, 180).  From the infection they claimed to obtain on average one viable phage per 
cell; thus the authors proposed that a physical transfer of viral RNA, along with the 
maturation protein, from the parent to the progeny must occur.  Another lab had also 
reported a low level of recycling of infecting phage RNA.  They observed a 3% transfer 
of infecting viral RNA to progeny virions, which they concluded was from re-utilization 
14 
 
 
of superinfecting phage RNA (33).  The physical transfer of the maturation protein was 
not studied in detail in any of these studies.  Additionally, the fate of the Q maturation 
protein has not been studied in detail.      
There is controversy over whether the nucleic acid is injected into the central 
lumen of the pilus upon ejection from the capsid or simply slides down the outside of the 
pilus (22, 119, 171).  Wong and Paranchych provided the strongest evidence that argues 
against RNA injection through the central core of the pilus.  The authors chemically 
treated R17 phage particles with ascorbate and Cu2+, which fragments the viral RNA.  
Electrophoretic analysis of the injected RNA (3H-labeled) under non-denaturing and 
denaturing conditions revealed that the RNA contained breaks that must have been held 
together by base pairing as the RNA was injected into the host cell (171).  This data 
suggests that the overall secondary structure of the viral RNA is maintained during 
infection.  The complex secondary of the viral RNA would be too large to traverse the 3 
nm central core of the F-pilus (161) and supports the notion of an alternative means of 
viral RNA delivery to the host cell.   
It was proposed that the F-pilus retracts to bring phage particles close to the 
vicinity of the bacterial membrane for viral RNA injection (31, 98); however, several 
lines of evidence argue against the pilus retraction model:  (i) destruction of the pilus 
occurs upon phage adsorption since the loss of F-pili correlates with an observed 
increase in pili fragments in the medium (116), (ii) visualization of bacterial mating pairs 
showed that exchange of genetic material occurs between cells that are not visibly in 
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close contact (111), and (iii) adsorption of chemically modified R17 phage resulted in 
both pili retraction and extension (28).  Taken together, this would argue against 
injection through the central lumen of the F-pilus but more likely support the notion that 
the pilus is just an appendage on which the RNA travels for delivery to the outer 
membrane.  Interestingly, a couple of groups have shown that purified viral RNA void of 
maturation protein produce plaques when spheroplasts are infected (62, 112).  However, 
another group reported that viral RNA is only infectious with non-spheroplasted cells if 
the maturation protein is also present (135).  This suggests that the maturation protein 
plays an active role in the injection process rather than just delivery of the viral RNA to 
the cellular membrane.  Moreover, Shiba and Suzuki (1981) found that fragments of 
viral RNA act as competitive inhibitors of maturation-bound RNA infection by 
physically occluding the pili binding domain of the maturation protein.  This suggests 
that other than adsorption to the pilus and ejection of the viral RNA from the capsid, 
binding of the F-pilus by the maturation protein is required for injection into cells.  
 
Replication 
Q RNA does not replicate through a DNA intermediate (30, 35, 55) but encodes 
a RNA-dependent RNA polymerase termed “replicase” (53, 142, 168) that is synthesized 
immediately from the viral RNA upon entry into the host cytoplasm (156).  After 
translation the replicase associates with host proteins:  EF-Ts, EF-Tu, and ribosomal 
protein S1 to form the replicase holoenzyme (71).  EF-Ts and EF-Tu are protein 
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synthesis elongation factors that are required for minus strand initiation (21, 88, 166).  
EF-Tu has a high affinity for guanosine nucleotides and is thought to assist in priming 
the pppG 5’-end of the minus strand for replication initiation (71, 166).  EF-Ts was 
hypothesized to assist in release the 5’-end of the nascent RNA product (71), but more 
recently, it was determined that it assists in stabilizing EF-Tu in the holoenzyme (73).  
Binding of the Replicase to the positive strand of the Q RNA is achieved by S1, which 
is a dissociable r-protein that acts as a bacterial translation factor (70, 71).  The 
Replicase holoenzyme, with the assistance of S1, also acts as a translational repressor by 
binding to a sequence in the central region of the viral RNA that overlaps the coat 
ribosome binding site (RBS) (81, 82, 103, 163).  This process prevents re-initiation of 
ribosomes at the coat start codon and clears the positive strand RNA.  This is important 
for minus strand replication, because c RNA synthesis cannot precede with ribosomes 
bound to the template (80, 82).  The minus strand serves as the template for new positive 
strand synthesis (128, 143), which does not require additional host factors besides the 
Replicase and EF-Ts/EF-Tu during in vitro synthesis (126).  Q requires an additional 
host protein, Hfq (HF-I), for synthesis from the positive strand (25, 45, 103).  HF-I is a 
bacterial protein that associates with Q RNA and remodels the secondary structure of 
the 3’-end of the plus strand to permit replication (90, 103, 134).  MS2-like phages do 
not require Hfq. 
Folding of the RNA into complex secondary structures during replication is 
thought to prevent annealing between the positive and minus strands (4, 139).  The 
Replicase holoenzyme holds the minus and positive strands in a configuration that 
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permits transient hydrogen bonding as chain elongation occurs.   It was determined that 
this bond formation is specific to the holoenzyme since treatment of the replicative 
complex with protein denaturants converts the intermediates into double-stranded RNA 
yet the same treatment of just positive and minus strands devoid of protein does not yield 
the same result (71, 167).  Replicase expression is repressed by Coat binding to a region 
distal to the coat cistron and overlapping the start of the replicase reading frame (10, 
148).  This regulation is phage-type-specific since f2 Coat has no effect on Q RNA 
replication (126).  Without repression, Replicase expression is upregulated and the 
amount of dsRNA is increased.   
Replicating RNA was determined to undergo coupled transcription and 
translation since replicating complexes were found in polysomes at the start of the 
infection cycle (48, 60, 61).  In vitro translation experiments supported this hypothesis 
when Staples and colleagues showed that the maturation protein can only be synthesized 
from replicating nascent strands that are shorter than 500 nucleotides in length (145).  
This suggests that ribosome initiation and elongation of the maturation protein precedes 
RNA folding into complex secondary and tertiary structures. The idea that the 
maturation protein gene is negatively regulated by RNA folding is supported by 
secondary structure analyses of the 5’-end of Q RNA, which revealed that long-
distance interactions sequester the RBS of A2 (7).  Groeneveld and colleagues had also 
shown that by decreasing or increasing hairpin loop length in the 5’end RNA secondary 
structures, the levels of maturation protein translation were modified, perhaps due to 
transient RNA folding kinetics (50).  Increasing the long-distance nucleotide base 
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pairing with the RBS, however, did not affect maturation protein translation levels, 
which suggests that the rate of the RNA folding is the primary determinant for ribosome 
accessibility to the maturation protein RBS,  which supports the hypothesis that 
translation occurs from nascent RNA molecules.  Recently, Jayant and colleagues 
determined that A2 expression is also regulated by ribosomal competition for binding 
since ribosomes had a higher affinity for the Coat RBS than that of the Maturation 
protein (66).  Both RNA folding kinetics and ribosomal competition for initiation could 
explain why maturation protein synthesis is only 2-5% that of Coat in in vitro translation 
experiments (92).         
Replication of viral RNA is dependent on the delicate balance between the 
coupled transcription and translation.  By isolating several amber mutants of phage f2, 
Zinder and Cooper had shown that phage with a nonsense mutation in the coat gene 
were unable to lyse cells of a nonsuppressor strain (see TABLE 1).  However, when this 
infected strain was subjected to a secondary infection i.e., “superinfected”, WT f2 phage 
lysed the cells (180).  This coat mutant produces little RNA early in infection (94); 
therefore, the simplest interpretation is that in the absence of active replication, 
superinfection is not inhibited.  Alternatively, a mutation in the maturation cistron of 
phage f2 had prevented superinfection of WT f2 phage from taking place (180).  This 
mutant undergoes normal infection and replication, but is unable to produce maturation 
protein to make infectious particles.  This suggests that Coat could bind to the RNA of 
superinfecting phage and prevent replication.  On the other hand, the su-11 allele of coat 
does not support  superinfection (TABLE 1) (180).  Su-11 is a mutation in coat that 
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produces excess amount of Replicase, which in turn, yields excessive dsRNA (94).  
Excessive Replicase produced from this mutant appears to have detrimental effects on 
superinfecting phage.  Whatever the factor is it has to be produced within a few minutes 
and be diffusible to inhibit replication of the superinfecting phage.  Interestingly, 
superinfection of MS2-infected cells by Q is permitted (91) and suggests that the 
mechanism of exclusion is phage-specific and not a host cell factor. 
 
 
  
TABLE 1.  f2 plating on a nonpermissive host.a 
Phage # Lysis Coat 
antigen 
(g/ml) 
RNA 
(P/ml) 
Viable 
yield 
Gene 
mutationb 
Superinfection 
Su-1 + 10-20   3x1012 1 Maturation - 
Su-3 - <1 <3x1010 <10-2 Coatc + 
Su-11 - <1 - <10-2 Coatc,d - 
f2 + 10-20   3x1012 8,000 None (WT)   n.d. 
n.d. not determined 
aData from Zinder and Cooper (1964). 
bAssignment based on mutation data. 
cPolar mutant that affects L (lysis protein) expression. 
dPolar affects on replicase expression (Lodish and Zinder 1966) 
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Virion morphogenesis 
The capsid of dsDNA phages is constructed by assembling the major capsid 
protein around an internal scaffold built over a dodecameric portal ring.  Once the 
prohead, consisting of the full complement of capsid proteins and cleared of the scaffold, 
an ATP-driven motor, the Terminase, catalyzes the packaging of the viral DNA, 
resulting in near crystalline-like states in the filled head (18).  In contrast, Leviviruses 
initiate virion morphogenesis with cooperative coat binding and nucleation of the viral 
RNA to form the capsid.  The viral RNA secondary structure has evolved not only to 
regulate RNA and protein synthesis but also to signal and support virion particle 
morphogenesis (106). 
Once viral RNA is synthesized the maturation protein binds to the 5’ and 3’-
ends, circularizing the RNA prior to nucleation of the capsid (40, 136).  It was shown 
through in vitro reconstitution of virion particles that the A protein must be bound to the 
RNA prior to coat nucleation to obtain infectious particles (78, 125).  Several lines of 
evidence indicate that the A protein, bound to the RNA, is located on the surface of the 
assembled virion particle.  The most direct evidence is that treatment of particles with 
various chemicals can cause dissociation of the maturation protein from the capsid (78).  
Moreover, the maturation protein is responsible for virion particle adsorption to the F-
pilus (93) so it must be accessible on the surface of the capsid. 
After a sufficient concentration of Coat has accumulated, the protein binds to the 
viral RNA not only to suppress Replicase synthesis but also to initiate capsid nucleation 
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(63).  Cooperative capsid assembly with the RNA then proceeds through a series of 
intermediate steps that were identified through in vitro assembly experiments (147, 164).  
The initial Coat-RNA complex, termed “complex I”, represses translation of the 
replicase protein.  The RNA at this stage is only partially protected from RNase activity, 
and addition of maturation protein to this complex prior to complete particle assembly 
yields infectious assembled virion particles.  The second complex, “complex II”, are 
fully assembled particles which were characterized by their sedimentation profile.  These 
particles are partially sensitive to RNase activity and do not produce infectious virions 
when A protein is added.  Intermediate stages between these two complexes were 
characterized in studies of MS2 assembly (106).  First, coat protein forms two different 
dimeric states for nucleation of the capsid, an asymmetric dimer (A/B) and a symmetric 
dimer (C/C), that differ with respect to the fold of the FG-loop (40).  The FG-loop 
connects two beta stands, F and G, and provide important contacts in the five-fold and 
six-fold axes of symmetry of the assembled particles (110).  These A/B and C/C 
complexes form hexamers and decamers of dimers that assemble with the RNA to build 
the virion capsid (40).  Initiation of the capsid begins when the Coat dimers bind the TR 
loop, a high affinity Coat nucleation initiation RNA stem-loop.  The authors determined 
that there are two possible assembly pathways in which the initial Coat-TR loop 
complex form:  one that follows formation of the hexameric dimer complex to build a 
face of the icosahedron or alternatively, the formation of the decameric dimer complex 
which builds a vertex of the icosahedrons; flux through either of these pathways is 
dependent on the relative RNA:Coat protein ratio.    
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For Leviviridae, the final assembled virion capsid is an icosahedron with T = 3, 
quasi-equivalence symmetry (27) comprised of 20 faces and 12 vertices, made up of 180 
copies of coat.  In Alloleviviruses, the minor capsid protein A1 accounts for ~15 copies 
of the 180 subunits of the capsid (96).  The amount of A1 incorporated into the capsid is 
close to the amount of vertices in the T = 3 symmetrical particle and could suggest a 
preference for A1 to assemble into Coat dimers that are precursors for the decameric 
vertices.  Support for this notion comes from the fact that the maturation protein is 
localized to a vertex for the MS2 phage (151).  Moreover, A1 is also a necessary capsid 
component that is required for infectivity (57) suggesting a direct involvement of A1 in 
proper assembly of A2 onto the virion.  Additionally, Toropova and colleagues (2011) 
reported an increase in density above vertices in particles imaged with cryo-EM.  This 
density could reflect A1 localization since it was also observed on the 3 fold axis of 
symmetry to a lesser degree.  
 
Lysis 
Attempts to identify the lysis proteins of Leviviruses began over 50 years ago 
when the ssRNA phages were first isolated.  Characterization of these phages was 
performed by genetic analysis of nonsense mutations. Zinder and Cooper (1964) had 
isolated mutants of a Levivirus phage f2, an MS2-like phage, that were deficient in lysis.  
Analysis of the mutants revealed that Coat was not produced although RNA was still 
synthesized (TABLE 1).  A suppressor mutation was obtained that reinstated Coat 
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production; however, the phages were still deficient in lysis.  In 1968 another group 
proposed that the Coat protein perhaps indirectly initiates lysis by activating an 
unidentified lysozyme (181).  It was not until three years after the genome of MS2 was 
sequenced that the lysis protein, L, was identified as a gene product from an alternate 
reading frame that overlaps the coat and replicase genes (3, 8, 105) (FIG. 3).  The host 
target of L is still unknown; however, it likely targets a step in cell wall 
maintenance/turnover since peptidoglycan precursor molecules are still incorporated into 
the cell wall (11, 58). 
Horiuchi and Matsuhashi (1970), performing genetic analyses of the 
Allolevivirus Q, isolated an amber nonsense mutant of A2, the maturation protein, that 
formed defective particles yet did not lyse cells (59).  This is in contrast to Leviviruses, 
where maturation protein nonsense mutants produce defective particles but support 
normal lysis in non-suppressing conditions (180).  Three years later, Ozaki and 
Valentine had linked lysis to cell wall synthesis inhibition when they determined that 
infection with Q prevented incorporation of peptidoglycan precursor molecules into the 
cell wall (112).   A2 was not identified as the lysis protein for Q until 10 years later (72, 
169).  The host target of A2 was discovered when Bernhardt and colleagues employed a 
genetic approach to identify which step of the cell wall synthesis pathway was blocked 
in Q infections (16) (FIG. 4).  The authors isolated survivors of induction of a cloned 
A2 gene and screened them for Q resistance.  Two mutants survived these series of 
screens and were termed rat1 and rat2 (resistant to A2).  Both isolates contained 
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FIG. 4.  Cell wall synthesis pathway.  MurA is the first committed step of the 
peptidoglycan synthesis pathway.  The enolpyruvate moiety is transferred from 
PEP to UDP-GlcNAc.  The product of this reaction is converted to UDP-
MurNAc by MurB.  UDP-MurNAc-pentapeptide (p5) is formed by addition of 
amino acid or derivatives by additional enzymes in the pathway.  The UDP-
MurNAc-p5 precursor is attached to undecaprenyl phosphate by MraY, 
thereby forming the Lipid I precursor molecule.  MurG generates the Lipid II 
precursor molecule by catalyzing the addition of GlcNAc to Lipid I.  Lipid II is 
then flipped across the membrane, and a glycosyltransferase (GTase) catalyzes 
polymerization of the nascent peptidoglycan chain.  The undecaprenyl 
phosphate is then flipped back across the membrane for further precursor 
subunit synthesis.  Lysis proteins are shown inhibiting a given step in the 
pathway:  Q A2 inhibits MurA and X174 E inhibits MraY.  The target of L 
is not known; however, the protein does not inhibit precursor subunit 
incorporation. 
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mutations that mapped to murA as a single amino acid substitution, L138Q.  Further 
evidence for MurA as the target of A2 was presented when uridine 5’-diphosphate-N-
acetylglucosamine (UNAG), the substrate of MurA, was found to accumulate upon A2 
induction from a plasmid.  The authors also determined that the time required from the 
point at which A2 inhibits cell wall synthesis to cellular lysis was approximately 20 
minutes.  Finally, MurA activity in a crude lysate was shown to be inhibited by intact Q 
particles, containing a single A2 protein on the surface of each virion.  Further support 
for an A2-MurA interaction was obtained when compensatory mutants were isolated 
from rare plaques of Q plated on the murArat strain.  The mutants were termed por 
(plate on rat), and were found to contain one of three amino acid substitutions:  L28P, 
D52N and E125G (89).  Preliminary studies on the por mutants revealed an increase in 
the amount of A2 expression (89).  Thus, the mutations may not provide residual effects 
that compensate for the L138Q mutation but rather affect the reaction equilibrium by 
increasing A2 expression.  
A model for lysis timing has been proposed, suggesting that lysis only occurs 
after the level of virion-associated A2 reaches that of MurA, allowing time for 
morphogenesis (54).  Previous work by C. Langlais implies that “free” A2 is the 
inhibitory molecule in an infection (89).  Quantification of MurA, total amount of A2 
produced and number of virion particles will shed light into how lysis timing is 
controlled during a Q infection. 
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Lysis gene regulation 
In all three cases of single gene lysis, total expression of the lysis protein is 
severely limited compared to the morphogenesis proteins (156, 173).  For phage X174, 
the lysis gene E is transcribed constitutively from all promoters; however, the protein’s 
overall translation level is severely limited by the fact that the E gene is embedded in the 
+1 reading frame of a highly expressed morphogenesis gene (6).   
In contrast, strict negative translational control mechanisms based on dynamic 
RNA structures have been invoked to down-regulate the production of both Q A2 and 
MS2 L (7, 50, 156).  For MS2, the translation of L is linked to Coat protein translation 
since the L gene does not have a Shine-Dalgarno sequence (74).  Two models were 
proposed for translation of L:  (i) a frameshifting model in which L is translated after 
early termination of Coat translation (74) and (ii) a lateral diffusion model that proposes 
after completion of Coat translation, the ribosomes diffusion along the RNA until a the L 
start codon is recognized (1, 9, 77).  Berkhout and colleagues found that destabilization 
of the hairpin loop that sequesters the RBS of L by translation of the coat gene precedes 
L translation (9).  Thus, position of the coat termination site is important in regulation of 
L translation levels (9, 156).  Klovins and colleagues (1997) also found that mutation of 
hairpin loops that do not alter the primary structure of the Coat protein greatly affect the 
fitness of the phage.  Selection of suppressor mutants revealed restoration of the RNA 
secondary structure which further supports the role of RNA secondary structure in lysis 
protein expression.    
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In vitro experiments indicated Q A2, as a maturation protein, is only translated 
from newly synthesized, nascent RNA strands (145).  It was shown that once the RNA 
exceeds 500 nt, the viral RNA adopts a very complex secondary structure that forms 
several long distance interactions that sequester the ribosomal binding site.  Increasing 
the amount of base pairing surrounding the RBS had no effect on the translation rate of 
A2 (50).  It was only when the length of the folding RNA stem-loop structures was 
modified that an effect on A2 expression was observed (122).  Thus, it was concluded 
that the rate of the RNA folding regulates the amount of maturation protein translation 
from the nascent transcribed viral RNA (127, 145).    
 
Mapping the lytic domain of A2 
Attempts at mapping the lytic domain of A2 have been reported by two groups 
(72, 89).  Karnik and Billeter (1983) were unsuccessful in identifying a functional 
truncation of A2.  In contrast, C. Langlais was able to identify a C-terminal truncation 
that consists of the first 179 residues of A2 still retains lytic activity.  An alignment of 
the maturation proteins from Alloleviviruses with that of Leviviruses, which have an 
alternative lysis protein, (FIG. 5) revealed that the region with the least amount of 
primary structure similarity lies in the first half of the protein.  This was also the region 
in which the ‘compensatory’ por mutations, discussed previously, were also mapped (16, 
89).   
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FIG. 5.  Alloleviviridae A2 and Leviviridae A alignment.  Alloleviviridae A2 proteins 
(phages:  NL95, SP, M11, and Q) and Leviviridae A proteins (phages:  MS2, fr, and 
BZ13) were aligned.  Alignment of the maturation proteins was performed with CLC 
Sequence Viewer (ref).  Conserved residues are shown in red and non-conserved 
residues are depicted with blue. 
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Interestingly the C-terminal domain of the maturation proteins had two regions of 
highly conserved residues from around residues 204-218 and 307-334.  These regions 
are more likely pili binding domains since the residues are highly conserved and 
dispensable for lytic function.  A third region that spans residues 140-187 is not as 
highly conserved but is present in the truncated A2 protein identified as retaining lytic 
function.  A truncation that consists of the first 171 residues does not retain lytic activity.  
Loss of activity can be explained by two possibilities:  (i) loss of a secondary structural 
element required for folding this N-terminal domain of A2 or (ii) deletion of part of the 
lytic domain.  Further experiments are needed to distinguish between these two 
possibilities.   
 
MurA 
MurA catalyzes the transfer of the enolpyruvyl moiety (EP) from 
phosphoenolpyruvate (PEP) to UNAG yielding two products, EP-UNAG and inorganic 
phosphate (Pi) (52) (FIG. 6).  Several catalytic states of MurA have been crystallized for 
E. coli and Enterobacter cloacae (93% identity, 97% similarity to E. coli):  (i) 
unliganded, open conformation (pre-catalysis state; PDB entries: 1DLG and 3SPB) (131, 
179), (ii) UNAG-bound state (PDB entry: 3KQJ, H. Han, unpublished; and PDB entry: 
3UPK) (179), (iii) UNAG-bound state with a covalent adduct formed between the 
catalytic Cys and PEP (PDB entry: 3SWA), (iv) fosfomycin-inhibited state with UNAG 
bound (PDB entry: 1UAE) (138), (v) a tetrahedral intermediate state with both UNAG  
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FIG. 6.  MurA catalysis.  Pathway modified from results reported previously 
(179).  Unliganded MurA (open conformation) binds UDP-N-
acetylglucosamine (UNAG) prior to binding phosphoenolpyruvate (PEP).  
Upon PEP binding a covalent adduct is generated with the catalytic Cys115 
prior to formation of the tetrahedral ketal intermediate (THI).  The 
enolpyruvate moiety (EP) is transferred to UNAG forming EP-UNAG and 
releasing inorganic phosphate (Pi) in the elimination reaction.  After release, 
PEP binds and forms another covalent adduct with Cys115.  MurA remains 
bound to EP-UNAG until displaced by either UNAG or UDP-N-acetylmuramic 
acid (UNAM), if the cellular [UNAG] is low.  MurA-PEP:UNAM is a dormant 
complex, and UNAM remains bound until cellular the [UNAG] increases.  The 
covalent catalytic pathway of MurA is highlighted with the dashed box.  An 
alternative, non-covalent catalytic pathway with PEP bound is depicted with 
arrows that are weighted less.  Changes in the previously reported pathway are 
shown with dashed arrows.  PEP is designated with an asterisk to note points 
of catalysis that fosfomycin inhibits.  Points in the pathway without available 
crystal structures are indicated with parentheses. 
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FIG. 7.  Structural view of MurA catalysis.  MurA is an induced fit enzyme 
with an open conformation (PDB entry: 1DLG) until UDP-N-
acetylglucosamine (UNAG) binding (PDB entry: 3KQJ), which induces a 
conformational change of the catalytic loop (shown as spheres) and converts 
the enzyme into a closed conformation.  Additional binding of 
phosphoenolpyruvate (PEP) (PDB entry: 1A2N) causes a slight conformational 
change in the catalytic loop as seen by the position of the catalytic Cys 
(highlighted in orange).  Fosfomycin is a dead-end inhibitor of MurA.  The 
structure of MurA-fosfomycin-UNAG (PDB entry: 1UAE) adopts a 
conformation similar to the UNAG-liganded MurA structure.  MurA catalysis 
proceeds through the primary pathway shown in FIG. 6.  Several steps were 
omitted here for simplification, which are depicted with a large bent arrow.  
PyMOL was used to generate figures (133). 
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and PEP liganded (PDB entries: 1A2N and 1Q3G) (43, 137), (vi) the EP-UNAG/Pi 
bound state (PDB entry: 1RYW) (44), and (vii) an EP-UNAGal-liganded conformation 
(containing the UNAG analog UDP-N-acetylgalactosamine) covalently bound to PEP 
(3SWI) (179).  These structures provide insight into the MurA catalytic cycle, which is 
summarized in FIG. 6.  Based on these structures, a major feature of the conformational 
changes associated with catalysis appears to be the dynamic behavior of the loop (FIG. 
7) containing the catalytic Cys residue at position 115.  Binding of UNAG is responsible 
for the major conformational change of the loop and UNAG binding is required  before 
PEP can bind (132) (179).   An additional structure showed that PEP is excluded from 
the active site by a covalent bond formation of fosfomycin with residue C115 of MurA 
and the C-3 hydroxyl of UNAG (138); this structure adopts a conformation similar to the 
UNAG-bound state.  Mutation of the C115 residue is the basis for fosfomycin resistance 
of Mycobacterium tuberculosis MurA (76) and suggests that MurA has an alternative 
pathway for catalysis that does not involve the covalent adduct to PEP (179) (FIG. 6), 
but no crystal structure is available for this intermediate.   
A dormant state of MurA has recently been identified in which the enzyme co-
purifies with uridine 5’-diphosphate-N-muramic acid (UNAM) and a covalent adduct 
formed with PEP (104, 179) implying an important regulatory role in vivo.  UNAM is 
the product of MurB the enzyme that acts immediately after MurA in the cell wall 
synthesis pathway (FIG. 6).  Both UNAM and EP-UNAG have an approximately 100-
fold lower Kd than that of UNAG (TABLE 2).  This higher affinity of substrates for 
MurA could be important in the regulation of MurA catalysis and should be factored in  
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vitro experimentation and may not reflect the state of catalysis in vivo.  Insight into the 
pathways in vivo can be obtained from calculating the percentage of ligand bound to 
MurA (θ) based on previously determined Kds and the cellular concentrations for the 
ligands with equation (1) (109): 
θ =      [L]      where [L] is the concentration of ligand 
      [L] + Kd      
Data for the binding equilibria for various ligands of MurA are listed in TABLE 2.  The 
data support that MurA is predominantly found in a covalent adduct with PEP since the 
calculated θ = 0.99.  This was the basis for drawing the catalytic cycle with PEP 
covalently attached as the primary pathway of MurA (FIG. 6).  The calculated θ value 
for UNAG (0.67) was lower than that of EP-UNAG (0.92) and UNAM (0.84-0.98).  This 
TABLE 2.  Cellular pools of MurA ligands. 
Substrate [L] (M) Kd (M) θ
a Reference 
UNAG 100 50 0.67 (100, 179) 
PEP 150 0.17b 0.99 (100, 179) 
EP-UNAG 2 0.17 0.92 (100, 179) 
UNAM 5-37 0.94 0.84-0.98 (99, 104) 
aSee text for equation (1). 
bValue is for UNAG bound MurA since the Kd for unliganded MurA (240 M) 
(132) is greater than the cellular pool of PEP suggesting an ordered addition of 
UNAM then PEP. 
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is surprising since it would seem that the percentage bound should be higher but these 
numbers reflect the percent bound without any other ligand considered in the calculation.  
The cellular pools of EP-NAG and UNAM are 10-fold higher than the prospective MurA 
Kd values for the ligands (TABLE 2), which suggests that these ligands are actively 
competing with UNAG binding.  This is supported by Mizyed and colleagues findings in 
which the authors performed competition experiments with UNAM that measured MurA 
activity in the presence of 100 M UNAG, the concentration of the cellular pool of 
UNAG (TABLE 2).  These analyses revealed that at ~ 6 M of UNAM MurA activity 
was reduced by ~ 25% and at ~ 12 M of UNAM approximately 95% reduction in 
activity was observed (based on Fig. 5b) (104).  The concentrations of UNAM used in 
these studies are between 7 and 10-fold the amount of the Kd value but within the range 
of the cellular pool of UNAM (TABLE 2) suggesting that UNAG is in direct 
competition with UNAM as a ligand for MurA. Taking this data into consideration the 
MurA catalytic cycle shows an equilibrium between the MurA-PEP adduct and the 3 
ligands (UNAG, UNAM, and EP-UNAG) (FIG. 6).  
 
Project Aims 
This work will address several gaps in our understanding of the Q infection 
cycle:  (i) How is A2 function regulated in vivo:  a) what form of A2 is inhibitory and b) 
at what point of an infection is cell wall synthesis blocked?  (ii) How does A2 inhibit 
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MurA:  a) is inhibition the result of an A2-MurA complex formation and b) can it be 
demonstrated with purified protein?    
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CHAPTER II 
THE REGULATION OF LYSIS IN Q INFECTIONS 
Introduction 
The three known types of simple phages with single-strand nucleic acid 
genomes:  Alloleviviridae (ssRNA; Q), Leviviridae (ssRNA; MS2) and Microviridae 
(ssDNA; X174), effect lysis by expression of a single gene without muralytic activity 
(15).  Of these, two are known to cause lysis by inhibiting an essential enzyme in the 
murein precursor pathway:  Q A2 inhibits MurA (16) and X174 E inhibits MraY (13).  
In both cases, lysis occurs when the host cell attempts to septate in the absence of murein 
synthesis.  The third, MS2 L, effects lysis by an unknown mechanism.   
Q has long been one of the paradigm experimental systems for studying viral 
RNA-dependent RNA polymerase and RNA evolution, in part because of its simplicity 
(20, 37-39).  The Q genome consists of only three genes, encoding four proteins:  
Maturation or A2, Coat, Read-through coat or A1, and Replicase (FIG. 8A).  A single 
copy of A2 is mounted on the Q virion, comprised of a T=3 capsid containing ~ 165 
copies of coat, ~15 copies of A1, and the 4.2 kb ssRNA (156).   Among the three simple 
phage systems, the Q lysis system is unique in that the lysis protein, A2, has other 
functions:  it protects the genomic RNA from RNase degradation (164), mediates 
specific adsorption to the F-pilus, and chaperones the genome into the host cytoplasm 
(83).  Since the other functions of A2 require binding to Q RNA, the phage particle, and 
the host F-pilus, an assortment of potential regulatory modes are possible in the infected 
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FIG. 8.  Q RNA.  (A) Q is a (+) ssRNA phage with a 4.2 kb genome.  
Replication of the chromosome is dependent on encoded replicase and four 
additional host proteins.  Q RNA is encased by three gene products: Coat, the 
major virion structural protein, A1 a minor component translated from read-
through of the leaky coat UGA stop codon, and a single copy of A2.  (B) RNA 
secondary structure of Q 5’-end (nt 1-860).  Stem-loops and long-distance 
interactions (LD) drawn and labeled according to Beekwilder and colleagues 
(7).  Single nucleotide substitutions of Q por mutants depicted with black dots 
with specific sequence substitutions shown in boxes (arrow).  Shine-Dalgarno 
(SD) 
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cell.  A2 expression is tightly regulated by extensive secondary structure surrounding its 
translational initiation region (7, 50) (FIG. 8B), and in vitro translation experiments 
indicate that A2 is produced only from nascent transcripts (127, 145).   
In 1983, Winter and Gold (169) revealed another function for this protein by 
showing that induction of A2 cloned on a medium copy plasmid was necessary and 
sufficient to induce host lysis.  Nearly 20 years later, Bernhardt and colleagues (2001) 
discovered that induction of a plasmid-borne cDNA copy of A2 caused cell wall 
synthesis to cease at ~20 minutes prior to lysis, indicating that A2 was acting as a 
"protein antibiotic" targeting murein biosynthesis.  To address the mechanism of Q 
lysis, survivors of A2 induction were screened for insensitivity to viral infection.  Two 
independent rat (resistance to A2) mutants were mapped to murA, which encodes UDP-
N-acetylglucosamine enolpyruvyl transferase, the enzyme catalyzing the committed step 
for the biosynthetic pathway of murein precursors.  Both rat alleles proved to have a 
single missense change, L138Q.  Biochemical studies of A2 were impeded due to 
insolubility of the protein apart from the capsid (15, 16).  However, MurA activity in a 
crude lysate was shown to be inhibited by intact Q particles.  This led to a model for 
regulation of lysis in Q infections in which A2 does not become inhibitory until fully 
assembled into the capsid (54).  
Here, we have examined the inhibition of virion-assembled A2 with purified 
MurA and quantified both MurA and A2 during the Q infection cycle.  The results are 
discussed in terms of a new model for regulation of lysis in Q infections. 
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Materials and Methods 
Bacterial strains and growth conditions 
The following Escherichia coli strains were used in this study:  XL1-Blue (140) 
was used for all plasmid constructions.  XL1-Bluerat cells (16) were used for phage 
infections. HfrH - relA1 spoT1 thi-1 lacIq fhuA::Tn10 (HfrH) and HfrH - relA1 spoT1 
thi-1 lacI
q1
 lacZ::Tn5 (HfrH lacZ::Tn5) served as lawns for bacteriophage plaque assays 
and cells for gradient induction, respectively.  HfrHrat construction was previously 
described (89).  ER2738 (F´proA+B+ lacIq (lacZ)M15 zzf::Tn10) fhuA2 glnV (lac-
proAB) thi-1 (hsdS-mcrB)5  (New England Biolabs) was used for phage propagation 
and protein expression.  E. coli strains were grown with aeration at 37°C in standard LB 
medium supplemented with 100 g ml-1 ampicillin, 40 g ml-1 kanamycin, or 10 g ml-1 
tetracycline when appropriate.  For Q infections, medium was supplemented with 2 
mM CaCl2. 
 
Plasmid construction 
Standard molecular biology techniques were performed as previously described 
(129).  Plasmids used in this study that were constructed previously are listed in TABLE 
3.  The plasmid pZA32-coat/A1 was generated by amplification of the coat and read-
through (A1) gene from pQm100 (102) with the primers:  A1-For and A1-Rev.  The 
PCR product was digested with KpnI and XbaI and ligated into pZA32 (96), similarly 
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digested.  To generate pZA32-A1, the coat stop was converted to the TGG Trp codon by 
site-directed mutagenesis (Stratagene) with primers:  A1-stop-W-For and A1-stop-W-
Rev.  Primers used in this study are listed in TABLE 4. 
 
 
 
 
TABLE 3.  Plasmids used in this study. 
Plasmid Reference 
pZE12-murA (16) 
pZE12-murAHis (89) 
pZE12-murABs (89) 
pZE12-A2 (89) 
pZE12-A2L28P (89) 
pZE12-A2D52N (89) 
pZE12-A2E125G (89) 
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MurA expression and purification 
ER2738 cells harboring pZE12-murAHis were grown at 37°C with aeration and 
induced with 1 mM IPTG for 3 hours.  Cells were collected by centrifugation at 4,000 xg 
for 15 minutes at 4°C, resuspended in buffer (0.1 M Tris-HCl [pH 8], 20 g ml-1 DNase 
and 10 g ml-1 RNase), and lysed by passage through a SLM-Aminco French pressure 
cell (Spectronic Instruments) at 16,000 psi.  The lysate was clarified by centrifugation at 
5,800 xg for 15 minutes at 4°C.  Protein was precipitated with 70% ammonium sulfate, 
collected by centrifugation at 5,800 xg for 10 minutes at 4°C, and resuspended with 
equivalent volume of buffer (0.1 M Tris-HCl, pH 8).  The crude protein sample was then 
applied to a Talon metal affinity resin (Clontech) and eluted with a 0 to 0.5 M imidazole 
gradient in the same buffer.  One-hundred drop fractions were collected with a micro- 
fractionator (Gilson).  Fractions were assessed for protein concentration (A280) and 
activity as previously described (97).  Fractions with the highest protein concentration 
TABLE 4.  Primers for A1 cloning. 
Primer Sequence 
A1-For GGGGTACCATGGCAAAATTAGAG 
A1-Rev GCTCTAGACTAAGCACGAGGAAC 
A1-stop-W-For GAACCCAGCGTATTGGACACTGCTCATTGCC 
A1-stop-W-Rev GGCAATGAGCAGTGTCCAATACGCTGGGTTC 
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and activity were pooled and stored as an ammonium sulfate precipitant at 4°C until 
further use.  All in vitro analyses use the oligo-histidine-tagged protein.  
 
Phage inactivation assay 
Q particles were purified as previously described (146).  4x1011 PFU of Q 
were mixed with 1 g of MurA.  A Q-only control as well as a sample including 1 g 
of bovine serum albumin (BSA) (Sigma) was prepared in parallel.  Samples were 
brought to 20 l with buffer and incubated at 37°C for 1 hour.  Samples were then 
brought to 1 ml with SM medium (129) supplemented with 5 mM CaCl2.  Ten-fold serial 
dilutions were prepared and 100 l of various dilutions were included in the bacterial 
overlay for plating comparison.  Plates were incubated at 37ºC for 6-8 hours and 
efficiency of plating was assessed.  RNaseA (Sigma, 1.25 ng l-1) was also included in 
the inactivation assay with purified particles and MurA.  
 
RNA release assay 
RNA release from virion particles was determined by addition of an inactivation 
sample containing MurA (7 g) and Q (6x1013 particles) in 100 l, incubated at 37°C 
for 1 hour, on top of a 5 and 50 percent sucrose step gradient (100 l).  The sample was 
run at 200,000 xg for 1 hour at 5ºC.  150 l was removed from the top of the gradient.  
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The remaining sample was removed and 50 l of buffer (0.1M Tris-HCl [pH 8.0]) was 
added to the tube to resuspend the pellet fraction.  All three fractions were assessed for 
nucleic acid (A260) and protein content (8% Tris-Tricine SDS-PAGE).  MurA and Q 
only controls were performed in parallel. 
 
MurA quantification 
Quantification of MurA was performed by standard SDS-PAGE and immune-
blotting procedures (51).  HfrH cellular samples were precipitated with 10% TCA and 
washed with acetone prior to resuspending with sample loading buffer and running on an 
8% Tris-Tricine gel.  Blots were probed with -MurA raised against the synthetic 
peptide:  CHGKRPKAVNVRTAP (GenScript) at 1:3,000 dilution and goat-anti-rabbit 
2° antibody (Pierce) at a 1:3,000 dilution.  The SuperSignal West Femto developer kit 
(Pierce) was used for chemiluminescent detection.  For a blotting control a murA 
knockout in which the chromosomal murA was replaced with a kanamycin cassette (23) 
was prepared via P1 transduction (101), with pZE12-murABs provided in trans, to 
generate HfrH murA::kan pZE12-murABs. 
 
A2 induction and quantification 
The critical concentration for A2-mediated lysis was determined by gradient 
induction of HfrH lacZ::Tn5 pZE12-A2 with IPTG at final concentrations:  0, 12.5, 25, 
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50, 100 and 1000 M.  Cell growth was monitored as A550 and samples were taken for 
TCA precipitation.  SDS-PAGE and immune-blotting was performed, as described 
above, with a 1:10,000 dilution of -A2 raised against a synthetic peptide:  
PKLPRGLRFGA (Bethyl Laboratories, Inc.) and 1:3,000 dilution of goat-anti-rabbit 2° 
antibody (Pierce).  An A2 standard was obtained by purifying inclusion bodies from cells 
expressing A2 protein.  The inclusion bodies were processed as previously described 
(113) and dissolved in 10 % SDS.  An amino acid analysis of the purified protein was 
performed by the Protein Chemistry Laboratory (Texas A&M University) to determine 
the concentration of the A2 in solution. 
Quantification of A2 during an infection was performed as described above, with 
samples of XL1-Blue cells infected with an input multiplicity of infection of 1 Q PFU 
per cell.  The amount of A2 per cell was determined by measuring the total amount of A2 
per ml, dividing by the total number of cells per ml, and multiplying by 1.6 to correct for 
the number of expected number of uninfected cells based on Poisson statistics.   
 
Released/intracellular titer 
To measure released PFU accumulation, 1 ml of culture was pelleted, and the 
supernatant was titered.   For intracellular PFU accumulation, pellets were resuspended 
in 3 ml of LB and subjected to disruption by passage through a French pressure cell as 
described above.  Serial dilutions of samples were prepared and an aliquot was added to 
an HfrH overlay. 
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MurA titration assay 
Protection was determined by infecting HfrH lacZ::Tn5 cells containing either 
pZE12-luc or pZE12-murAHis with a cell to PFU ratio of 1.  Gradient induction of cells 
was performed, as described above, to determine the concentration at which MurA 
expression protects against a Q infection.  Samples were taken at 60 minutes post 
infection for MurA quantification.  At the end of a single round of infection (140 
minutes), a sample was removed, centrifuged and the supernatant was titered for 
unadsorbed particles.   
 
 
 
 
 
 
FIG. 9.  Q particles are inactivated by incubation with MurA in vitro.  Plating 
of purified Q particles (panel A) in an HfrH overlay.  Incubation of Q with 
MurA (panel B) or BSA (panel C) was performed prior to plating. 
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FIG. 10.  Ki determination for Q inactivation by MurA.  Percent viability of 
Q was measured after 30 minutes incubation with increasing amounts of 
MurA.  Ki was determined by plotting viability vs. MurA concentration by 
plotting with KaleidaGraph and fit to the equation (2) (124):  
 V   = Vmax[A] + VoKm + Vo[A] 
     Km + [A] 
Where [A] is [MurA] and Vo is the percent viable when [A] = 0.  Vmax is m1, 
Vo is m2, and the Ki (Km) is m3 with M units. 
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Results and Discussion  
MurA inactivates Q particles  
Q inhibition of MurA activity has previously been addressed (16), but the effect 
of MurA association on Q plating has not.  Incubation of purified Q with a three-fold 
excess of purified MurA prior to titering resulted in a reduction in plating efficiency of 
two orders of magnitude (FIG. 9A-B).  In contrast, BSA did not reduce the plating 
efficiency (FIG. 9C), indicating that the inactivation is specific to MurA.  Simple 
occlusion of virion particles to the F-pilus by MurA can be ruled out since the virion- 
MurA complex is diluted by 5x105-fold before inclusion in the overlay.  Based on this 
inactivation reaction, the apparent affinity of MurA for the virions was found to be ~ 40 
nM in vitro (FIG. 10).  The inactivation reaction was further examined by fractionation 
on a sucrose step gradient.  Analysis of the fractions showed RNA release from a Q 
sample that was incubated with MurA; release was not observed with a virion only 
control (FIG. 11 and TABLE 5).  The simplest interpretation is that MurA binding 
causes a conformational change of the maturation protein, allowing RNA release thus 
inactivating the particle.  This result raises the question of how the two roles of A2, as 
maturation protein and sole lysis protein, are balanced such that Q progeny are not 
inactivated during the latent period. 
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TABLE 5. Sucrose gradient fraction analysis of Q RNA release. 
MurA (A280) Q (A260) Q + MurA (A260) 
Fraction 
1 
Fraction 
2 
Fraction 
1 
Fraction 
2 
Fraction 
3 
Fraction 
1 
Fraction 
2 
Fraction 
3 
0.061 0.023 0.008 31.4 1.10 0.255 43.3 1.49 
 
FIG. 11.  Sucrose gradient analysis of Q particles incubated with MurA.  
MurA and Q incubation reactions were applied to a sucrose step gradient and 
centrifuged.  All fractions were resolved on SDS-PAGE and assessed for 
nucleic acid content (TABLE 5). 
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FIG. 12.  MurA quantification.  5 x 108 HfrH cells (lane 3) were blotted with 
HfrH pZE12-murABs (lane 1) and HfrH murA::kan pZE12-murABs (lane 2) for 
determination of MurA band (asterisks).  MurA standards were included:  7.5, 
15, 22.5, and 30 ng in lanes 4-7 respectively.   
TABLE 6. Critical concentration of A2 to induce host lysis. 
Level of 
induction     
(M IPTG)a 
Lysis (+/-) A2 molecules/ 
cell 
Time of 
analysis        
(min) 
0 
12.5 
25 
50 
100 
100 
1000 
- 
- 
- 
- 
+ 
+ 
+ 
n.d. 
n.d. 
2.2 x102 
2.3 x102 
3.6 x102 
4.9 x102 
1.4 x103 
n.d. 
n.d. 
60 
60 
15 
30 
15 
n.d. not determined 
apZE12-A2 
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Quantification of MurA and A2 in vivo 
To address this question, it was necessary to quantify both MurA and A2. The 
endogenous level of MurA was determined by quantitative Western blotting, using 
purified MurA as a standard.  The result, 390 ± 30 molecules per cell (FIG. 12), is in 
agreement with another determination of 410 MurA molecules per cell by MS profiling 
(65).  Similarly, the level of A2 necessary for lysis was estimated by gradient induction 
of an IPTG-inducible plasmid clone.  Lysis onset is observed at 40 minutes at 100 M 
IPTG (FIG. 13).  At this level of induction, ~350 and ~500 A2 molecules accumulate, 
per cell, at 15 minutes and 30 minutes (TABLE 6).  Lysis occurs even earlier at higher 
levels of inducer (FIG. 13).  These results indicate that the cell is committed to lysis 
when free A2 titrates out the available MurA. 
 
Quantification of A2 accumulation during infection 
The context of the viral infection cycle might change the stoichiometry of A2 and 
MurA, especially considering that in this framework, A2 has multiple roles.  To address 
this issue, A2 was quantified during a Q infection of the male strain XL1-Blue.  The 
total A2 concentration was found to exceed that of MurA by 30 minutes after infection 
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FIG. 13.  Plasmid-borne A2 induces cellular lysis.  A2 lysis and accumulation 
was measured at various concentrations of inducer:  pZE12-luc control (1 mM: 
X); pZE12-A2 (uninduced: white diamonds, 12.5 M: white squares, 25 M: 
white circles, 50 M: black diamonds, 100 M: black squares, and 1 mM: 
black circles). 
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(TABLE 7).  Lysis was monitored both by culture turbidity and the release of Q virions 
(FIG. 14A-B).  Lysis onset was not observed until 80 minutes, suggesting that a 
component of the Q infection cycle is sequestering A2 from binding to MurA.  
 
Por mutants produce A2 more rapidly and cause early lysis 
Further evidence addressing the relationship between the rate of A2 production 
and lysis timing was obtained from analysis of Q por (plates on rat) mutants (16).  These 
TABLE 7.  Q A2 quantification. 
Time               
(min) 
XL1-Blue 
Q A2WT Q A2L28P  Q A2D52N  Q A2E125G  
15 
30 
45 
60 
75 
n.d. 
5.1 x102 
7.5 x102 
1.2 x103 
2.9 x103 
n.d. 
1.0 x103 
n.d. 
n.d. 
n.d. 
n.d. 
1.7 x103 
n.d. 
n.d. 
n.d. 
n.d. 
1.3 x103 
n.d. 
n.d. 
n.d. 
n.d. not determined 
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FIG. 14. Q and Q por phenotype of infected cells.  (A) Infection of XL1-Blue 
cells with Q.  Reduction in cellular mass accumulation is observed starting at 30 
minutes with a maximum at 80 minutes with phage input MOI of 1.  A2 
accumulation (white diamonds) was quantified at intervals during infection.  (B) 
Q has a higher released PFU titer after a single infection cycle than Q por.  (C) A2 
accumulation during infection of XL1-Blue.  Loading was normalized to total 
volume.  Samples were taken at time points listed (min).  (D) Q por mutants have 
an earlier lysis phenotype in XL1-Blue infected cells.  Q infection reproduced 
(panel A) with Q por infections.  Symbols:  (X) cells only control, QA2WT 
(black circles), Q A2L28P (black diamonds), Q A2D52N (black squares), and Q 
A2E125G (black triangles) 
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FIG. 15.  Q  por plating phenotype.  Phage were plated on HfrH (left) and 
HfrHrat (right):   Q (panels A-B), Q A2L28P (panels C-D), Q A2D52N 
(panels E-F), Q A2E125G (panels G-H). 
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mutants were isolated as rare plaque-formers on the murArat host (FIG. 15).  Eight 
independent mutants were obtained (TABLE 8); sequence analysis revealed that each 
had mutations in the N-terminal domain of the A2 gene.  The simplest interpretation was 
that missense changes in A2 could suppress the defect in the inhibition of the MurA
L138Q 
mutant and implied that the N-terminal domain of A2 carried the lytic determinant.  This 
would be consistent with the observation that the principle differences between the lytic 
maturation proteins of Q and other Alloleviviridae and the non-lytic maturation proteins 
of the Leviviridae are in the N-terminal region.  However, clones of the A2
por alleles, 
although fully lytic in the parental host, failed to support inducible lysis in the murArat 
background (FIG. 16).  Moreover, Western blot analysis of samples taken from 
TABLE 8. Q  por sequence. 
Q A2
por Mutationsa 
Substitution D52N 
gat>aat 
E125G 
gag>ggg 
 F412S 
ttt>tct 
D52N 
gat>aat 
P66P 
cca>ccg 
 H67R 
cat>cgt 
L28P 
ctc>ccc 
D52N 
gat>aat 
D52G 
gat>ggt 
D52G 
gat>ggt 
L28P 
ctc>ccc 
a(I. Wang, unpublished) 
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FIG. 16.  Cloned A2
por does not lyse a MurArat strain.  XL1-Blue rat cells 
harboring plasmids:  pZE12-A2 (black circles), pZE12-A2L28P (black 
diamonds), pZE12-A2D52N (white squares), and pZE12-A2E125G (white 
triangles) were induced with 1 mM IPTG.  A2 and A2
por accumulation at 20 
minutes is shown in inset. 
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infections with the por mutants clearly showed that A2 was accumulating more rapidly 
than in WT infections (FIG. 14C).  These results indicated that the ability of por mutants 
to support plaque-formation on the murArat background is due to a higher rate of 
synthesis of A2 in vivo, rather than an altered ability to inhibit MurA
L138Q.  Inspection of 
the secondary structure map of the A2 mRNA shows that each of the mutations alters a 
base-pairing element that is predicted to be involved in repressing translational initiation 
(FIG. 8B).  Thus, the por mutations derange the normal translational control of A2. 
Based on the previous results with the inducible cDNA clones of A2 (FIG. 13), 
we expected that the por mutants would show earlier lysis in infections of WT cells.   
FIG. 14D shows that this is indeed the case, with lysis onset occurring 30-45 minutes 
earlier than with WT Q.  The early lysis also reduces the yield of progeny (FIG. 14B), 
demonstrating that the normal regulation of lysis is important for the fitness of Q.  With 
all three por alleles, the level of total A2 production by 30 minutes is equal to or greater 
than that achieved by the WT phage at 60 minutes, accounting for the earlier lysis 
(TABLE 7 and FIG. 14C). 
 
MurA over-production blocks lysis but does not inactivate intracellular virions 
The low concentration of cytoplasmic MurA suggests that it should be possible 
to block Q lysis by expressing MurA in excess from a plasmid clone.  To determine the 
amount of MurA needed for protection during an infection, gradient induction of HfrH  
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FIG. 17.  Expression of MurA protects during a Q infection.  HfrH lacZ::Tn5 
cells were infected with Q containing various plasmid constructs:  pZE12-luc 
(induced 1 mM: white squares), pZE12-murA (uninduced: white triangles; 
induced 12.5 M: black circles, 25 M: white circles, 50 M: black diamonds, 
100 M: white diamonds, 1 mM: white triangles).  Black squares: uninfected 
pZE12-luc strain (induced 1mM).    IPTG was added simultaneously with 
virion particles. 
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lacZ::Tn5 pZE12-murAHis infected cells was performed, and MurA accumulation was 
quantified.  As predicted, a delay in lysis was observed with basal expression of MurA 
from the plasmid as compared to the vector control (pZE12-luc), and lysis was 
completely abolished in cells induced at IPTG concentrations ≥ 12.5 M (FIG. 17).  This 
confirms that the amount of A2 normally deployed for inhibiting MurA is less than 1 x 
103 molecules (TABLE 9).  We next asked whether MurA levels in vast excess over the 
level sufficient to block lysis completely would lead to inactivation of intracellular Q 
particles and thus a reduced yield of progeny.  Whether the experiments were done in a 
WT or a murArat background, intracellular virion production was unaffected, compared 
TABLE 9. Quantification of MurA protection during a Q infection. 
Plasmid Level of 
induction     
(M IPTG) 
MurA 
molecules/ 
cell 
Released 
PFU/ml 
(140’) 
Lysis 
(+/-) 
PFU/cell 
(90’)a 
pZE12-luc 1000 3.9 x102 4 x1010 + 880 ± 110 
pZE12-murAHis 0 
12.5 
25 
50 
100 
1000 
4 x102 
1 x103 
4 x103 
5 x103 
1 x104 
3 x104 
3 x1010 
2 x109 
3 x108 
4 x107 
2 x107 
5 x106 
+ 
- 
- 
- 
- 
- 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
760 ± 90 
n.d. not determined 
adetermined in XL1-Bluerat strain 
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with a control in which Luciferase was produced (TABLE 9), despite MurA reaching 
levels ~100 fold higher than the normal endogenous level.   This suggests that, during 
the latent period, the progeny virions are protected from inactivation by MurA and 
consequently, virion-mounted A2 is not the molecule that binds and inhibits MurA but 
rather free, unassembled A2.  
 
Particles are protected by a soluble viral component 
The simplest explanation for intracellular virion particle protection from MurA 
inactivation is that the particles are simply sequestered from MurA during 
morphogenesis; however, this does not seem to be the case since in vitro particle 
inactivation in a cell-free phage lysate, as opposed to purified phage particles, does not 
occur (FIG. 18) suggesting that a soluble, intracellular factor protects the particles.   
FIG. 18.  Q lysate is not inactivated by MurA.  (A) Q lysate only and (B) Q 
lysate incubated with MurA 
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Addition of bacterial lysate to the in vitro inactivation experiment with purified Q and 
MurA did not provide the particles from protection against MurA inactivation (FIG. 19), 
which implies that a viral component protects the particles from inactivation.  Viral Coat 
and A1, which interact with A2 in the assembled particle, can be excluded as the soluble 
factor since expression of these proteins had no effect on the A2 lysis phenotype (FIG. 
20), and leave the two other viral factors that are produced during an infection:   
FIG. 19.  Bacterial lysate does not protect Q from inactivation by MurA.  (A) 
Purified Q only, (B) Purified Q incubated with MurA, (C) Purified Q with 
bacterial lysate, and (D) Purified Q with bacterial lysate incubated with MurA 
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FIG. 20.  A2 lysis is not regulated by Coat or A1.  A2 was expressed from 
pZE12-A2 in the presence of pZA32-luc (circles: uninduced, white; induced 
black), pZA32-coat/A1 (diamonds: uninduced, white; induced, red), and 
pZA32-A1 (squares: uninduced, white; induced, blue).  Plasmids induced with 
1 mM IPTG at Time = 0’. 
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 (i) Replicase and (ii) Q RNA as potential candidates.  The Replicase is an unlikely 
candidate since it is present only at ~ 500 copies during an infection (154) and associated 
with replicating viral RNA at polysomes (48).  
 
Virion particles are protected from in vitro inactivation by Q RNA 
When the in vitro particle inactivation experiment was repeated with another 
purified Q preparation, no inactivation was observed (FIG. 21A).  This was 
unexpected, especially since the phage preparation had a protein composition 
indistinguishable from the inactivation-competent preparation (FIG. 21B).  Moreover, 
we noticed that variability in the sensitivity to MurA-mediated inactivation could be 
correlated with losses in PFU titer and the concomitant increase in released Q RNA.  
To ask whether released virion RNA could be exerting a protective effect, the insensitive 
preparation was treated with RNase and then re-tested for MurA inactivation.  The 
results were unambiguous; RNase treatment restored sensitivity to MurA (FIG. 21C) 
suggesting released RNA protects particles from MurA inactivation.  However, attempts 
to reconstitute MurA protection by supplementing with purified Q RNA were 
unsuccessful (not shown).  These results suggest that Q RNA, in a conformation 
obtained from spontaneous release from the virion, can protect Q virions from MurA 
inactivation in vitro, and raises the possibility that Q RNA may play a protective role 
for progeny virions during the latent period. 
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Lysis inhibition of Q 
Characterization of a lysis inhibited (LIN) state for lytic phage infections has 
been limited to T4 and homologs.  However, a review of the ssRNA phage literature 
revealed a reference to a LIN state for an MS2-like phage, R17 (41).  The authors had 
FIG. 21.  Q is protected from MurA inactivation by RNA.  (A) A non-
inactivating virion preparation was incubated prior to plating: phage only (left), 
plus MurA (right).  (B) Protein content was assessed by resolving the 
inactivating (lane 1) and non-inactivating Q preparations (lane 2) with SDS-
PAGE.  (C) RNase degradation restores particle inactivation.  The non-
inactivating phage only control (left) was incubated with RNase (middle) and 
with RNase including MurA (right). 
65 
 
 
found that with an input MOI of 10 that < 0.1% of cells had lysed after a 90 minute 
infection cycle.  Another group had found with another MS2-like phage, f2, that if phage 
were incubated for 10 minutes and then washed to remove the phages, lysis is observed 
at 90 minutes (117).  It is interesting that presumably continuous infection by the phage 
in the sample that was not washed is enough to delay lysis.  Ellis and colleague also 
reported viral replication in the LIN state of the R17 phage with particle accumulation 
suggesting that the LIN state does not perturb viral replication.   
Here, in the process of studying the timing of lysis in Q infections, a state of 
LIN was observed with Q when the input MOI of phage was ≥ 10 (FIG. 22).  This LIN 
state is not due to reduction in the level of A2 since the infected cells under all conditions 
had comparable amounts of the lysis protein.  This unexpected observation makes a case 
for LIN being a general capability of ssRNA phages, since the Alloleviviridae and the 
Leviviridae effect lysis by fundamentally different pathways.   LIN cultures continue to 
accumulate cellular density as judged by the absorbance profile over time (FIG. 22), 
which suggests the mode of the LIN state is not due to the cessation of division.  Given 
that the two lysis proteins accumulate in different compartments, with L localized to the 
cellular envelope and A2 remaining free or particle-bound in the cytoplasm, it is unclear 
how cell division can be affected.     
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FIG. 22.  Q lysis inhibition.   HfrH cells were infected with variable input 
MOI:  1 (squares), 10 (diamonds) and 100 (triangles) at Time = 0’.  A2 
accumulation at 60’ was measured (inset).  Infected cultures were pelleted to 
remove contaminating phage in the medium prior to sample analysis. 
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Discussion 
A2 inhibition of MurA and MurA-inactivation of Q:  Models for regulation 
Biochemical studies on A2 have been retarded because of the insolubility of the 
protein.  The only soluble form of A2 known is the single molecule on the surface of the 
infectious Q particle (16, 156).  While using this form of A2, we were surprised to find 
that Q virions are rapidly and efficiently inactivated by contact with purified MurA 
(FIG. 9).  This immediately cast doubt on the simplest idea proposed for the regulation 
of lysis in Q infections, in which infectious virions simply accumulated until they 
titrated out the MurA complement of the cell.  The next simplest model would be that A2 
was produced in a large excess over MurA, so that attrition of infectious virions by 
contact with MurA would be negligible. However, our measurements of both MurA and 
A2 revealed that (i) MurA is present at ~400 molecules per cell and (ii) Q-infected cells 
produce A2 at levels roughly comparable to the total number of MurA molecules and 
assembled virions.  Moreover, the two to three-fold increase in the accumulation rate of 
A2 exhibited by the Q
 por mutants leads to a much shorter and less productive infection 
cycle (FIG. 14B and D).  Based on previous work indicating that A2 is translated only 
off of nascent RNAs (127, 145) and also recent findings that Q assembly initiates with 
a single molecule of A2 binding both 5’ and 3’-ends of the genomic RNA (40), we 
suggest a third model where A2 is synthesized off of nascent RNAs in slight 
stoichiometric excess.  The vast majority of A2 molecules are thus committed to 
assembly and only a small fraction is free and able to form the inhibitory complex with 
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MurA.  Accordingly, the early lysis phenotype of the por mutants simply reflects a 
derangement of this stoichiometric balance, such that free A2 is available in quantity 
from much earlier in the infection cycle.   
Several studies have indicated that the ability to adapt to conditions that require 
altered lysis timing is an important fitness factor for a bacteriophage (24, 158, 177). The 
simple model proposed above can accommodate this requirement by mutational changes 
that alter the level of excess A2 production over the unit stoichiometry, presumably by 
changes analogous to the por mutations but less drastic.  ssRNA phage have complex 
RNA secondary structures that not only protect the RNA from RNase activity but also 
assist in regulation of protein expression (9, 50, 156).  Analysis of the RNA’s 5’-end 
hairpin structures revealed that the rate of folding and not the stability of base pairing 
surrounding the ribosome binding site was the regulatory factor in the level of 
maturation protein expression (50).  Therefore, mutations that change the kinetics of 
RNA folding provide plenty of opportunities for adjusting the amount of protein 
expression which could also remain silent in terms of A2 function.  Alternatively, in the 
MS2 system, translation of the L protein is regulated by a hairpin structure that contains 
the ribosomal binding site (9, 156).  Destabilization of this hairpin by ribosomal 
translation of coat precedes L translation; however, the position of coat termination 
relative to the L initiation site is important.  Insertions or deletions between these two 
sites greatly affect the level of L translation (9) and could be a means to adjustment of 
lysis protein expression levels to evade selective pressures from the host during an 
infection.    
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Protection of intracellular virions 
The A2-MurA lysis system would seem to have clear advantages:  (i) MurA is a 
highly conserved enzyme essential for the supply of murein precursors, and its inhibition 
leads inescapably to lysis (69, 76, 150).  (ii) Moreover, as noted above the nature of the 
complex Q RNA structure confers facile adjustability to lysis timing.  However, this 
system also confers MurA sensitivity to purified Q virions.  Although this was 
unexpected, in retrospect the sensitivity of virions to a protein ligand is consistent with 
A2 roles in recognition of pilin and release of the genomic RNA during infection (119, 
155, 156).  This raises the issue of whether or not there is substantial attrition of viable 
virions during a normal infection.  This seems unlikely considering that the number of 
MurA molecules available in vivo to inactivate Q virions would be comparable to the 
average yields of viable virions per cell (59, 154).  Moreover, massive over-production 
of MurA, although completely blocking lysis, has no effect on the viability of the 
intracellular virions (TABLE 9).  These data indicate that there is an intracellular factor 
that protects the A2 molecule mounted on the virion from MurA, a conclusion supported 
by the finding that purified MurA does not inactivate Q particles present in a crude 
lysate (FIG. 18). 
The identity of the protecting factor(s) is unknown.  Candidates might include 
protein chaperones that bind the virion in such a way to sterically protect A2 from MurA.  
Phages frequently make use of cellular chaperones during morphogenesis (121); 
however, we favor a phage-specific factor, based on the inability of bacterial lysate to 
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protect particles from MurA inactivation (FIG. 19) and differences in MurA sensitivity 
of purified Q preparations.  Most preparations are fully sensitive to MurA (FIG. 9A-B) 
whereas other preparations are insensitive (FIG. 21A-B); this insensitivity is often 
associated with increased age of the preparation (data not shown).  Importantly, the 
insensitivity is associated with significant levels of released RNA and can be fully 
reversed by RNase treatment (FIG. 21C) and suggests a simple model for protection 
based on the RNA-protein intermediates in the Q assembly pathway.  Q viral 
morphogenesis begins with a single A2 molecule binding both ends of the genomic 
RNA, after which coat progressively nucleates capsid formation (40, 156).  We suggest 
that the exposed RNA of one or more of these intermediates can bind a completed virion 
in trans in such a way as to protect the A2 molecule from MurA interaction.  We were 
not able to recapitulate MurA protection by the addition of purified Q RNA, suggesting 
that RNA-protein interactions and consequent RNA secondary or tertiary structures 
might be required for the protective effect.  Efforts to localize the interaction surfaces on 
the MurA and A2 molecules may clarify these issues and are currently underway.    
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CHAPTER III 
STRUCTURE AND FUNCTION ANALYSES OF A2
 
Introduction 
In vitro characterization of proteins is dependent on the use of soluble protein; A2 
characterization is limited in this respect since the protein is insoluble apart from 
assembly on the virion capsid.  Identification of A2 as the lysis protein was achieved by 
the fact that purified Q particles, with a single copy of A2 on the surface, efficiently 
inhibited MurA (16).  However, the use of virion particles to further characterize the A2-
MurA interaction is impractical in the sense that the particle themselves are too large for 
many techniques.  Moreover, from previous results (Chapter II), it was determined that 
an interaction between MurA and A2 on the surface of the particles releases viral RNA.   
 
Materials and Methods 
Bacterial strains and growth conditions 
The Escherichia coli strains used in this study:  XL1-Blue, ER2738, HfrH 
lacZ::Tn5, and BL21(DE3) are previously described (Chapter II)(153).  Standard 
                                                 
Part of the data reported in this chapter is reprinted with permission from Understanding 
the lytic function of A2:  The maturation protein of ssRNA bacteriophage Q, C. 
Langlais, 2007, Texas A&M, College Station, TX. [2007] 
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molecular biology techniques were performed as described elsewhere (129).  Bacterial 
growth conditions were described previously (Chapter II). 
 
 
TABLE 10.  Primers used in construction of A2 fusion proteins. 
Primer Sequence 
A2SalI-For CGCGTCGACATGCCTAAATTACCGCGTGG 
A2BamHI-Rev CGCGGATCCTCAACGCTTTACGGGTTGGG 
GST-For GATATACATATGTCCCCTATACTAGGTTAT 
EK1-A2-For GGCTCCGGTGATGACGACGACAAGATGCCTAAA
TTACCGCGTGG 
EK1-A2-Rev CCACGCGGTAATTTAGGCATCTTGTCGTCGTCAT
CACCGGAGCC 
RV-Xba-Bam-A2-Rev TGGTAAGGATCCTCTAGAGATATCTTATCAACG
CTTTACGCGTTGGG 
SeqPET TAATACGACTCACTATAGGG 
KpnI-NdeI-A2-For GTATAAGAGGTACCACATATGCCTAAATTACC 
A2-Rev-BamHI GCAGCCGGATCCAGTTTCA 
A2-A hybrid-For AAGGCGTACACTGCTGTTAAGCGTGGCGATTTA
CGTGC 
A2-A hybrid-Rev CACGAGCGCAATCAGTAAAAGCCCGAGATATTT
TATAGTCTC 
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Plasmid construction 
Construction of pZE12-murAHis and pZA31-murABs (murAA) was previously 
described (89).  The pZA31-murABs plasmid has a PLtet0-1 promoter which is 
constitutively on in a tetR- background.  Amplification of A2 for sub-cloning into vectors 
was performed as previously described (89).  A2 fusion constructs were generated 
previously (89) but were not published.  Primers used in construction of A2 fusions are 
listed in TABLE 10.  To generate pETSUMO-A2 the A2 gene was amplified using 
primers:  A2SalI-For and A2BamHI-Rev digested and ligated into pTB146 (kindly 
provided by Tom Bernhardt, Harvard) cut with SalI and BamHI.  pETGST-A2 was 
constructed via SOE PCR (153) with three separate PCR reactions:  (i) the GST-tag was 
amplified with GST-For and EK1-A2-Rev using pET41 (Novagen) as the template, (ii) 
A2 gene amplification was achieved with primers EK1-A2-For and RV-Xba-Bam-A2-
Rev, (iii) SOE PCR was performed with the purified gene products above and primers:  
GST-For and RV-Xba-Bam-A2-Rev.  Digestion of SOE PCR product and ligation into 
pET41 vector was achieved with NdeI and BamHI.  pETNusA-A2 was prepared similarly 
to GST-A2 with primers: (i) SeqPET and EK1-A2-Rev for NusA-tag amplification from 
pET44 (Novagen), (ii) EK1-A2-For and RV-Xba-Bam-A2-Rev for A2 amplification, and 
(iii) T7 promoter and RV-Xba-Bam-A2-Rev with purified gene products for SOE PCR.  
Purified SOE PCR product was digested with NdeI and BamHI for ligation into pET44.  
To generate pETMBP-A2, the A2 gene was amplified using KpnI-NdeI-A2-For and A2-
Rev-BamHI primers. The PCR product was digested with NdeI and BamHI and ligated 
into p202 (pET28b-MBP vector with a TEV protease cleavage site, kindly provided by 
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Dr. Sacchettini, Texas A&M University), similarly digested.  pETMBP-A21-189 was 
generated by insertion of amber codon at position 190 via site-directed mutagenesis with 
the following primers:  A2190-420For and A2190-420Rev, described previously (89).  
An A2 (166-173)-A (158-165) hybrid was constructed by ExSite PCR (ref) with the 
following primers:  A2-A hybrid-For and A2-A hybrid-Rev with pZE12A2 for the 
template, previously described (89). 
 
Protein expression and purification 
To test fusion protein functionality, cellular mass accumulation of induced 
BL21(DE3) pLysS (Novagen) cells harboring a plasmid borne copy of A2 truncations 
and/or fusions were monitored over time as described in the previously (Chapter II).  
Induction of proteins was performed with 1 mM final of IPTG unless otherwise 
indicated.  Protein accumulation was assayed by TCA precipitation, SDS-PAGE, and 
immune-blotting analyses as previously described (Chapter II).   
To assist in toxic protein accumulation for expression analyses, A2 fusion 
proteins were co-expressed with Bs MurAA.  Expression of A2 fusion proteins were 
performed at 37°C for 3-4 hours and/or at 16°C for 18 hours.  Solubility of the A2 fusion 
proteins were determined by analysis of distribution between the supernatant and pellet 
fractions of disrupted cells post centrifugation, 12,000 xg for 15 min at 4°C; 25 ml of 
culture, harvested by centrifugation at 16,000 xg for 15 min at 4°C, was resuspended in 
3 ml of buffer and disrupted as previously described (Chapter II).  Buffers used for 
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solubility included 20 g ml-1 DNase, 5 mM MgCl2, and protease inhibitor cocktail 
(Sigma):  SUMO-A2 (10 mM sodium phosphate [pH 7.4] and 100 mM NaCl), GST-A2 
(0.1 M Tris [pH 8.45] and 100 mM NaCl), NusA-A2 (0.1 M Tris [pH 8.45] and 100 mM 
NaCl), and MBP-A2 (20 mM Tris-HCl [pH 8], 150 mM NaCl, 10% glycerol).  All 
protein induction was performed with 1 mM IPTG, final, but for expression at 16°C cells 
were chilled in an ice water bath for 1 hour prior to induction.   
For protein purification analyses, 250 ml of culture was pelleted as above and 
resuspended in 6.25 ml of buffer for lysis (listed above). The clarified lysate, centrifuged 
as above, was filtered with 0.45 m filter prior to loading onto a column.  Talon resin 
(Clontech) was used for purification of proteins with a His-tag.  Elution was performed 
with the above buffers including 200 mM imidazole.  Low imidazole (20 mM) washes 
were performed prior to elution.  For amylose resin (Amylose High Flow resin, NEB) 
purification of MBP-A2, the cellular pellet was resuspended in lysis buffer (20 mM Tris-
HCl [pH 8], 150 mM NaCl, 1% glycerol, 1 mM EDTA, 20 g ml-1 DNase, 10 g ml-1 
RNaseA, and protease inhibitor cocktail (Sigma)) and eluted with buffer (20 mM Tris-
HCl [pH 8], 150 mM NaCl, 1% glycerol, and 10 mM maltose); 0.2 % glucose was 
included in medium for protein expression that is purified with amylose resin.   
Expression and purification of MurA was described previously (Chapter II).   
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Fusion cleavage assay 
Proteins containing the MBP fusion (2 M) were incubated with10 g of MBP-
TEV-protease (kindly provided by V. Kuznetsov, Texas A&M University) in protease in 
PBS buffer (10 mM sodium phosphate [pH 7.4], 100 mM NaCl, and 1 mM DTT) 
overnight at 4°C.  Solubility of proteins was assessed by centrifugation of cleaved 
protein.  An aliquot of samples was removed prior to centrifugation at 18,000 xg, 15 
minutes at 4°C.  Supernatant was removed and the pellet was resuspended in equivalent 
volume of buffer.  Fractions were analyzed with SDS-PAGE and immune-blotting, 
probed with the -A2 antibody. 
 
MurA activity assay 
MurA activity was performed as previously described (16, 97) with the following 
modifications:  MurA was assayed in the presence of various fusion proteins. 
 
Circular dichroism analysis 
To assess the secondary structure content of A2, circular dichroism (CD) was 
performed on equal molar concentrations (4 M) of MBP, MBP-A2 and MBP-A2
1-189 
dialyzed in PBS without DTT.  Data were collected with a 1 mm cuvette using an Aviv 
(model 62DS) instrument.  A buffer spectrum was obtained and subtracted from the raw 
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data.  Mean residue ellipticity (MRE) was calculated for each protein (49).  
Deconvolution of the data was performed with K2d (2), and the global alpha-helical 
content of A2 was determined with the equation (3): 
(MBP % of construct)(% alpha helix of MBP) + (A2 % of construct)X = % alpha 
helix of fusion 
where X is the percent of A2 alpha helical content.   
 
Results and Discussion 
Function and structure analyses of A2 fusion proteins 
Characterization of A2 has been limited due to the insolubility of the protein, 
apart from the assembled virion particles.  One way of obtaining soluble protein for in 
vitro analyses is to purify the protein as a hybrid fusion protein.  There are several 
proteins that have been well characterized as fusion proteins including:  small ubiquitin-
related modifier (SUMO), glutathione S-transferase (GST), MalE or maltose-binding 
protein (MBP), and N-utilization substance A (NusA).  Each fusion protein varies in the 
ability to perform as a fusion tag to increase solubility and potential to assist in protein 
folding.  Also, each construct contains a site for specialized protease cleavage to remove 
the fusion tag.  The SUMO-specific protease, Ulp1, recognizes a Gly-Gly motif at the C-
terminus of the tag, and cleavage of the protein from the tag leaves only the native 
protein without unwanted residues.  GST tags have been shown to provide some  
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protection against intracellular protease degradation (157).  MBP and NusA have similar 
ability to solubilize proteins and assist to some degree in folding of the fusion partner 
(108).   
All fusion constructs are N-terminal tags (FIG. 23).  SUMO-A2 (62 kDa) is the 
smallest fusion construct with an N-terminal His-Tag; the construct does not contain a 
linker between the two proteins.  GST-A2 (80 kDa) is the second largest construct; the 
chimera has a 57 aa linker that contains both a His-tag and S-tag with Thrombin and 
Enterokinase (EK) cleavage sites.  NusA-A2 (110 kDa) is the largest fusion construct 
with an N-terminal His-tag; the 49 aa linker of this construct also contains both the His-  
FIG. 23.  A2 fusion constructs.  Primary structure organization of A2 fusions:  
SUMO (blue), GST (green), NusA (purple), and MBP (yellow).  All constructs 
are N-terminal fusions to A2 (red).  Linkers are depicted with tags and 
(protease cleavage sites):  Enterokinase (EK).  Length of linkers and fusion 
proteins are listed in parentheses. 
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FIG. 24.  A2 fusion protein lysis phenotype.  BL21(DE3) pLysS containing A2 
fusion constructs for expression were induced at Time = 0 minutes with 1 mM 
IPTG, final.  (A) SUMO-A2 (B) GST-A2 (C) NusA-A2 (D) MBP-A2 
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tag and S-tag with Thrombin and EK cleavage sites.  The MBP-A2 (93 kDa) construct is 
smaller than the NusA-A2 with a 29 aa linker that contains a TEV protease cleavage site. 
 
Functional analysis of A2 fusion proteins in vivo 
To determine whether A2 fusion proteins were functional in vivo, cultures 
carrying chimeric constructs SUMO-A2, GST-A2, MBP-A2, and NusA-A2 were induced 
and monitored for optical density over time (FIG. 24).  All four fusion proteins lysed at 
~ 25 minutes, which was the same lysis timing of A2 expressed with a T7 promoter (89); 
thus, A2 lytic activity is not affected by having a large fusion tag tethered at the N-
terminus of the protein.   
 
 Purification of soluble fusions of A2 
SUMO-A2 
At 37°C, the SUMO-A2 construct exhibited poor expression (FIG. 25), with 
soluble material representing no more than 50% of the total.  Expression at 16°C 
increased the amount of SUMO-A2 (FIG. 25); however, ~ 90% of the protein was 
insoluble.  SUMO-A2 was thus abandoned as a construct for A2 purification. 
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FIG. 25.  SUMO-A2 solubility at 37°C and 16°C expression.  SUMO-A2 (62 
kDa) is labeled with an asterisk. (T) Total fraction, (S) supernatant after 
centrifugation, and (P) pellet after centrifugation 
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GST-A2 
Total expression of GST-A2 at 37°C was higher than for SUMO-A2 (FIG. 26), 
but ~ 90% of the protein was found to be insoluble.  Decreasing the temperature of 
expression increased the amount of soluble protein to ~ 70%, but there appeared to be an 
increase in a potential degradation product at ~ 60 kDa (FIG. 27).  Since expression of 
the fusion protein at 16°C increased the yield of soluble protein, purification was   
FIG. 26.  GST-A2 and NusA-A2 solubility at 37°C expression.  GST-A2 (80 
kDa) is labeled with double asterisks and NusA-A2 (110 kDa) is labeled with a 
single asterisk.  (T) Total fraction, (S) supernatant after centrifugation, and (P) 
pellet after centrifugation 
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FIG. 27.  GST-A2 and NusA-A2 solubility at 16°C expression.  GST-A2 (80 
kDa) is labeled with double asterisks and NusA-A2 (110 kDa) is labeled with a 
single asterisk.  (T) Total fraction, (S) supernatant after centrifugation, and (P) 
pellet after centrifugation 
 
84 
 
 
  
FIG. 28.  GST-A2 Talon resin purification.  Purification fractions were run on 
an SDS-PAGE:  Total lysate (T), lysate supernatant after centrifugation (S), 
lysate pellet after centrifugation (P), column flow through (FT), column wash 
(W), and eluate (E) from Talon resin.  GST-A2 (80 kDa) is labeled with an 
asterisk. 
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performed with the lower temperature expression conditions (FIG. 28).  Eluates from the 
metal affinity purification contained species that co-eluted with GST-A2 at apparent 
molecular masses of 65, 60 and 50 kDa, suggesting that the GST fusion does not protect 
A2 from proteolytic degradation.  Another possibility is that the degradation is from 
protease activity upon disruption of the cells and not due to in vivo activity during or 
after translation.  There was also a considerable amount of protein contaminants that 
were removed in the low imidazole wash, which also partially removed the GST-A2.  
The absorbance spectrum of the purified protein also revealed a shift in the maximum 
from 280 nm to 260 nm, suggesting a large amount of nucleic acid contamination (FIG. 
29).  A2 is known to bind within its own coding mRNA; therefore, it is not surprising 
that RNA would co-purify with the protein.  The yield of the purified GST-A2 protein 
was 4.5 mg/L; however, this concentration may be an over-estimate, since the 
absorbance at 280 nm may reflect partial RNA absorbance.  
FIG. 29.  GST-A2 absorbance spectrum.  GST-A2 has maximal absorbance at 
260 nm. 
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NusA-A2 
The NusA-A2 fusion exhibited protein expression and insolubility characteristics 
similar to GST-A2 for inductions and growth at 37°C (FIG. 26).  An apparent 
degradation product ~ 80 kDa was detectable for expressions done at 37°C.  Expression 
at 16°C increased the fusion protein solubility to about 40% (FIG. 27).  The apparent 80 
kDa degradation product was also reduced with expression under these conditions.  A 
considerable amount of the fusion protein was observed in the flow-through fraction.    
FIG. 30.  NusA-A2 Talon resin purification.  Purification fractions were run on 
an SDS-PAGE:  Total lysate (T), lysate supernatant after centrifugation (S), 
lysate pellet after centrifugation (P), column flow through (FT), column wash 
(W), and eluate (E) from Talon resin.  NusA-A2 (110 kDa) is labeled with an 
asterisk. 
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This could be from sequestering of the His-tag in the chimeric protein or saturation of 
binding capacity on the column.  Three prominent protein species were eluted from the 
column in the low imidazole wash, which included a considerable amount of the full 
length fusion protein.  Perhaps the two other species are degradation products since a 
band ~ 50 kDa was also observed for GST-A2.  Eluates from IMAC affinity purification 
of the fusion protein also contained the 50 kDa protein contaminant (FIG. 30); however, 
overall there appeared to be less proteolytic degradation with this fusion compared to the 
GST fusion.  The absorbance of the protein had a maximum at 280 nm rather than 260 
nm (FIG. 31), unlike GST-A2 suggesting that there is not significant RNA 
contamination.  The yield of the purified NusA-A2 protein was 0.8 mg/L which was 
significantly less than GST-A2.    
FIG. 31.  NusA-A2 absorbance spectrum.  NusA-A2 has maximal absorbance at 
280 nm. 
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FIG. 32.  MBP-A2 purification with Talon resin.  Purification fractions were 
run on an SDS-PAGE:  Total lysate (T), lysate supernatant after centrifugation 
(S), lysate pellet after centrifugation (P), column flow through (FT), column 
wash (W), and eluate (E).  MBP-A2 (93 kDa) is labeled with an asterisk. 
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MBP-A2 
MBP-A2 was expressed at 16°C and purification with both Talon and amylose 
resin was performed in collaboration with, V. Kuznetsov.  With Talon resin 
chromatography, ~ 90% of the protein was found in the flow-through fraction of the 
column (FIG. 32), suggesting that the His-tag is sequestered in the chimeric protein; this 
was also observed with the NusA-A2 construct (FIG. 30).  With amylose resin  
FIG. 33.  MBP-A2 purification with Amylose resin.  Fractions from 
purification were run on an SDS-PAGE:  Total lysate (T), lysate supernatant 
after centrifugation (S), lysate pellet after centrifugation (P), column flow 
through (FT), column wash (W), and eluate (E).  MBP-A2 (93 kDa) is labeled 
with an asterisk. 
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chromatography, the amount of protein bound to the resin was increased to ~ 40% 
(compare E fraction of Talon and amylose resin in FIG. 32 and FIG. 33).  There was a 
significant amount of degradation at the C-terminus of the A2 segment with this fusion 
construct, as judged by immune-blotting with an antibody specific for the extreme N-
terminus of A2 (FIG. 34).  Addition of protease inhibitor in the purification buffer prior 
to cellular disruption significantly reduced the amount of degradation (FIG. 35).  The 
MBP-A2 fusion protein has a maximal absorbance at 270 nm (FIG. 36), which suggests 
there is a small amount of contaminating nucleic acid since purified MBP alone has a   
FIG. 34.  Western blot of MBP-A2 purification with Amylose resin.  MBP-A2 
purification fractions were assessed by immune-blotting with the α-A2 
antibody.  The antibody is specific for the first thirteen residues of A2. 
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FIG. 36.  MBP-A2 absorbance spectrum.  MBP-A2 has maximal absorbance at 
270 nm. 
FIG. 35.  MBP-A2 purification with protease inhibitor cocktail.  SDS-PAGE of 
MBP-A2 (93 kDa) purification with protease inhibitors included in the lysis 
buffer:  Total lysate (T), lysate supernatant after centrifugation (S), lysate 
pellet after centrifugation (P), column flow through (FT), column wash (W), 
and eluate fractions (E).   
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maximal absorbance at 280 nm (FIG. 37 and FIG. 38).  The amount of nucleic acid 
contamination is significantly less than that of GST-A2 which had a maximal absorbance 
at 260 nm (compare FIG. 36 and FIG. 29).  Addition of RNase to the purification buffer 
for MBP-A2 did not have an effect on the absorbance of the protein, suggesting that the 
RNA contamination it is limited to a small fragment protected from exogenous RNase 
by A2.  The yield of purified MBP-A2 was 11 mg/L for amylose resin purification, which 
was the highest out of all the fusions tested.   
FIG. 37.  MBP purification with amylose resin.  MBP (48 kDa) purification 
fractions were run on an SDS-PAGE:  Total lysate (T), lysate supernatant after 
centrifugation (S), lysate pellet after centrifugation (P), column flow through 
(FT), column wash (W), and eluate (E). 
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Based on these criteria, the MBP-A2 construct was chosen for further 
biochemical analysis in the following chapter.  A parallel construct with the A2
1-189 lytic 
truncation domain was also constructed. 
 
Optimization of MBP-A2 production 
Small organic molecules that assist cells in offsetting damaging effects from 
osmotic stress are termed osmolytes.  These molecules assist in stabilizing protein and 
preventing aggregation during protein folding (64).  The effect of osmolyte inclusion in 
culture medium was also tested with MBP-A2 expression at room temperature (FIG. 39).  
All osmolytes tested increased the amount of protein expressed.  Benzyl alcohol had the 
most effect on protein expression, but the majority of the protein as in insoluble, ~ 70%.    
FIG. 38. MBP absorbance spectrum.  MBP absorbs maximally around 280 nm. 
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Addition of osmolytes also appeared to reduce the amount of proteolytic cleavage after 
cellular disruption since bands at approximately 45 and 40 kDa were not observed in 4 
out of 5 of the osmolyte conditions tested (glycerol, proline, glycerol & proline, and 
trehalose); however, some potential degradation product was seen in the benzyl alcohol 
insoluble fraction.  Alternatively, these lower molecular weight bands could be proteins 
in which expression is affected by inclusion of osmolytes in the medium since there are 
significantly more protein bands visible in the no osmolyte control.  It would be 
interesting to see if addition of osmolytes to cultures with protein expression at 16°C 
would also reduce the amount of proteolytic degradation of A2.  
FIG. 39.  MBP-A2 osmolyte expression test.  Solubility of fusion protein was 
tested under growth conditions (LB, 0.5M NaCl; expressed at room 
temperature) with different osmolytes:  0.1% v/v Benzyl alcohol (BA), 1% v/v 
glycerol, 1 mM proline, 1% v/v; 1 mM glycerol & proline (Gly & Pro), and 1 
mM trehalose.  MBP-A2 (93 kDa) expression is labeled with an asterisk. 
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FIG. 40.  MBP-A2 and MBP-A2
1-189 fusion cleavage.  SDS-PAGE analysis of 
MBP-A2 and MBP-A2
1-189 cleavage products before centrifugation:  Total (T) 
and after centrifugation:  Supernatant (S) and Pellet (P).  Cleaved:  A2 (*), A2
1-
189 (**), and MBP (48 kDa); uncleaved MBP-A2 (93 kDa), and MBP-A2
1-189 
(66 kDa) 
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Cleavage of A2 domains from MBP chimera 
In an attempt to obtain soluble A2 material, the purified fusion proteins were 
subjected to proteolytic cleavage using the TEV protease.  TEV protease treatment of 
MBP-A2 resulted in insoluble A2 (pellet, FIG. 40); whereas, cleavage of MBP-A2
1-189 
produced soluble protein under the conditions assayed (supernatant, FIG. 40).  However, 
even for MBP-A2
1-189, scaling up at the level of the cleavage reaction or concentrating 
the cleaved protein resulted in insoluble protein.  Concentration of MBP-A2 also showed 
aggregation, as judged by cloudiness of the concentrated material; however, 
centrifugation at 18,000 xg for 15 minutes did not pellet the aggregates.  A2 appears to 
have hydrophobic characteristic since it aggregates when tethered to a large fusion 
protein.  Dialysis of this solution in PBS reduced the amount of visible aggregation 
without significantly changing the concentration.  Perhaps high concentrations of 
phosphate mimic RNA, a ligand of A2, thereby causing the protein aggregate to 
dissociate.         
 
Functional analysis of A2 fusion protein in vitro 
Inhibitory activity of the fusion proteins was assessed directly by measuring 
MurA activity.  In these experiments, MurA activity was assayed by release of inorganic 
phosphate, a product of MurA catalysis (FIG. 6).  This assay is laborious since it is an 
endpoint assay where samples are removed at various times from the reaction and 
individually processed.  A MurA concentration was chosen in order to avoid excessive   
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FIG. 41.  GST-A2 and NusA-A2 inhibition of MurA.  MurA (1 M) specific 
activity alone or in the presence of GST-A2 (30 M) or NusA-A2 (2 M). 
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time in processing, but by doing so this reduced the ratio of fusion protein:MurA that 
could be tested because solubility limitations of the fusion proteins.   
GST-A2 (30 M) reduced approximately 66% of MurA (1 M) activity (FIG. 
41).  The samples of this reaction had a high background, probably due to the large 
amount of contaminating RNA.  Alternatively, NusA-A2 at a lower concentration (2 M) 
was able to reduce MurA (1 M) activity by 20% (FIG. 41).  This fusion protein appears 
to be more efficient since only a 2-fold excess was able to reduce the activity of MurA 
by one-fifth compared to GST-A2 with 15-fold more protein than MurA was able to 
reduce activity by two-thirds.  NusA-A2 also had significantly less background in the 
reactions than that of GST-A2.   
MBP-A2 (1.8 M) reduced the activity of MurA (0.2 M) by about 20% when 
compared to a MBP (1.8 M) control (FIG. 42).  This is only a 9-fold molar excess of 
fusion protein to MurA.  Surprisingly, the activity of MurAL138Q was increased by 25% 
compared to the MBP control (FIG. 42).  Perhaps MBP-A2 binds the L138Q mutant in 
such a manner that it does not inhibit the enzyme but rather stabilizes the protein in such 
a manner that the enzymatic activity is increased.  Binding of A2 to the mutant will be 
addressed in the following chapter.   
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FIG. 42.  MBP-A2 inhibition of MurA.  Specific activity of MurA and 
MurAL138Q (0.2 M) assayed in the presence of MBP (1.8 M) or MBP-A2 
(1.8 M).  Reactions performed in triplicate. 
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FIG. 43.  Circular dichroism analysis of MBP-A2 and MBP-A2
1-189.  CD 
spectrum of equivalent molar concentrations of:   MBP (red circles) (4 M), 
MBP-A2 (blue circles) (4 M), and MBP-A2
1-189 (black circles) (4 M). 
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Characterization of the A2 fusion structure 
 CD was used to characterize the secondary structure of the MBP-A2 fusion 
protein, and the percent of contributing alpha helical content of A2 was determined 
according to the equation listed in the Materials and Methods section.  First, the 
experimental conditions and deconvolution program were validated with MBP by 
comparing the data to the published spectra  (47), which indicated an alpha-helical 
content of 36%,  and the crystal structure of MBP, in which ~ 40% of the residues are in 
FIG. 44.  Secondary structure prediction of A2.  Primary structure of A2 shown 
with alpha helices labeled with purple and beta sheets with yellow.  JPred3 was 
used for secondary structure prediction.  Putative Arg rich motif (ARM 
domain) is labeled with a black bar.  BindN was used for RNA binding motif 
predictions. 
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an alpha helix (144).  Analysis of the MBP-A2 fusion protein revealed an increase in the 
MRE magnitudes at 208 nm and 222 nm (FIG. 43), which are characteristic minima for 
alpha helices (75), suggesting a loss in the alpha helical content of the fusion.  The 
contributing alpha helical percentage for A2 was determined to be about 26%; whereas, 
the contributing percentage for a C-terminal truncation, A2
1-189 (FIG. 43), was 36% 
alpha-helical.  The values correlate well with the secondary structure prediction analysis 
(Jpred3) (29) of both the full length A2 and the A2
1-189 truncation in which approximately 
one-third of both proteins are predicted to be alpha helical (FIG. 44).  
 
Probing the A2 lytic domain 
Previous work has shown that the lytic domain of A2 is in the N-terminal 179 
residues of A2 (FIG. 45) (89).  The structural elements of this segment were predicted to 
be alpha helix-6 beta sheets-3 alpha helices (FIG. 44).  Although the N-terminal 1-179 
truncation is fully lytic, the next largest fragment, 1-171, is not (FIG. 45).  This 
truncation includes 5 residues of a predicted 30 aa long alpha helix that spans residues 
147-176.  This helix could be the functional domain of A2, i.e., the major determinant for 
inhibitory binding of MurA and that by truncating the helix, lytic function is lost.  This 
region also is predicted to bind RNA (BindN) (160) and contains a putative arginine-rich 
motif (ARM domain) (149) (FIG. 44), in that there are 8 Arg and 1 Lys residues, spaced 
every 3 to 4 residues between residues 166 and 185.  Earlier, RNA binding was  
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FIG. 45.  A2 Fragment analysis.  Full length A2 is 420 aa.  Truncation data was 
reprinted with permission (89) for comparison.  *Data obtained from 
collaborator, (R. Kongari).  A2 truncations depicted as solid bars.  Internal 
deletions of the protein are shown as dashed lines.  Functional (red) and non-
functional (black) 
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FIG. 46.  A2-A hybrid lysis phenotype.  A2-A hybrid lysis phenotype was 
compared to an A2 control:  A2-A hybrid (white circles), A2 (black squares), 
and uninduced control (X).  HfrH lacZ::Tn5 cells harboring either pZE12-A2-A 
or pZE12-A2 were induced with 100 M IPTG (final) at Time = 0’. 
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proposed to be one mode by which A2 is regulated (see Chapter II).  This raises the 
attractive notion that the putative ARM domain could also be the lytic domain of A2, and 
that RNA-dependent regulation of A2 activity might simply reflect the occlusion of the 
MurA interaction surface.  To test this possibility, an A2-A hybrid was generated where 
residues 165-173 were replaced with the aligned residues 158-165 of MS2 A (FIG. 46); 
this replacement eliminates 4 of the 8 Arg residues.  Analysis of the A2-A hybrid 
revealed that the protein retained full lytic function (FIG. 45), which falsified our 
hypothesis.  Moreover, an A2133-189 fragment was also tested and found to be non-lytic 
(FIG. 45).  Therefore, this predicted alpha helical domain does not appear to be the lytic 
domain of A2 and is probably more important for stabilizing the tertiary structure of the 
protein by acting as a scaffold for beta sheet assembly.   
Review of the A2 truncation data showed that when the first 32 residues were 
removed from the N-terminus, the resultant protein lost lytic function.  Perhaps the N-
terminal helix as well plays an important role in maintaining the tertiary structure of the 
protein by functioning as a scaffold for the putative beta sheet domain.  An alignment of 
the maturation proteins from Leviviruses and Alloleviviruses revealed that the least 
conserved region between the lytic maturation proteins of the Alloleviviridae and the 
non-lytic maturation proteins of the Leviviridae  is a predicted beta-sheet domain in the 
N-terminal half of the protein (FIG. 44).  All of the truncation data support the notion 
that the lytic domain is comprised of beta sheets that are supported by a series of 3 alpha 
helices; thus, by removing or deleting part of the alpha helices the protein is unable 
maintain the proper tertiary structure nor inhibit MurA.  
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CHAPTER IV 
INHIBITORY MECHANISM OF THE Q LYSIS PROTEIN A2
 
Introduction 
The Allolevivirus Q produces a single protein A2 to effect bacterial lysis, in 
addition to serving as a structural component of the virion (FIG. 8).  Unlike dsDNA 
phages that produce muralytic enzymes to degrade the cell wall, A2 inhibits MurA, an 
enzyme that catalyzes the first committed step in cell wall synthesis (16).  The key 
genetic result that led to this conclusion was the isolation of a dominant mutant resistant 
to Q lysis that mapped to the murA locus.  This mutant, designated as rat1 (resistant to 
A-two) was shown to be a Leu to Gln change at position 138 of MurA.  In addition, 
Bernhardt and colleagues showed that MurA expression in trans protected cells from 
lysis during a Q phage infection.  Moreover, purified Q particles were able to inhibit 
MurAWT activity, but not MurArat activity, in a crude extract.  Q mutants that were able 
to overcome the rat mutant lysis block were isolated and designated as por (plates on 
rat).  These mutants were postulated to be compensatory for the L138Q mutation in the 
A2-MurA interface (16).  However, recent biochemical and genetic evidence has 
indicated that the suppressor phenotype of these mutants is due to translational up-
                                                
Part of the data reported in this chapter is reprinted with permission from Understanding 
the lytic function of A2:  The maturation protein of ssRNA bacteriophage Q, C. 
Langlais, 2007, Texas A&M, College Station, TX. [2007] 
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regulation of A2, deriving from disruption of regulatory RNA stem-loop structures 
(Chapter II). 
To address the question of how lysis is regulated in a Q infection, a model was 
proposed in which A2 lysis function was not fully realized until assembled into the 
capsid of the phage particle (54).  However, previously we have shown that MurA 
actually inactivates Q particles, indicating that virions are not likely to be involved in 
lysis (Chapter II).  Instead, quantitative analysis of the infection cycle indicated that free, 
unassembled A2 is the inhibitory molecule of MurA.  Characterization of the mechanism 
of MurA inhibition has been hindered due to the insolubility of A2 apart from assembly 
into the virion capsid.   
In this study we address the requirements for an A2-MurA interaction.  The 
results are discussed in terms of the molecular state of MurA when it is bound by A2. 
 
Materials and Methods 
Bacterial strains and growth conditions   
The following E. coli strains were used in this study:  XL1-Blue (140) was used 
for all plasmid constructions, HfrH lacZ::Tn5 served as lawns for bacteriophage plaque 
assays, and ER2738  was used for phage propagation and protein expression.  
Descriptions of these strains are listed in Chapter II.  E. coli strains were grown with 
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aeration at 37°C in standard LB medium supplemented with 100 g ml-1 ampicillin, 40 
g ml-1 kanamycin, or 10 g ml-1 tetracycline when appropriate.  
 
Plasmid construction   
Several plasmids used in this study were described in the preceding chapters:  
pZE12-murA, pZA31-murABs, and pETMBP-A2.  Alleles of murA* used in the MurA 
bioassay were constructed by site-directed mutagenesis (140) into pZE12-murA with 
primers listed in TABLE 11.  Construction of additional murA* alleles is described 
elsewhere (6). 
 
Protein expression and purification 
Expression and purification of MurA and MBP-A2 were described in previous 
chapters:  Chapter II and Chapter III, respectively.  
 
MurA activity assay 
Q inhibition of MurA was performed as previously reported (16) but with 2 g 
of purified MurA (0.4 M) instead of cell lysate and 60 l of Q (4 x 1013 physical 
particles) (~0.7 M A2) in a 100 l reaction.   
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TABLE 11.  Primers for construction of murA* alleles. 
Allele Sequence 
V87R FOR:GCACCTTACGATCTGCGTAAAACCATGCGTGC 
 REV:GCACGCATGGTTTTACGCAGATCGTAAGGTGC 
K88E FOR:CCTTACGATCTCGTTGAAACCATGCGTGCTTC 
 REV:GAAGCACGCATGGTTTCAACGAGATCGTAAGG 
T89R FOR:GATCTGGTTAAACGCATGCGTGCTTC 
 REV: GAAGCACGCATGCGTTTAACCAGATC 
A154R FOR:GGTCGTTTGAAAGGTCGTCATATCGTGATGG 
 REV:CCATCACGATATGACGACCTTTCAAACGACC 
H155R FOR:CGTTTGAAAGGTGCACGTATCGTGATGGATAAAG 
 REV:CTTTATCCATCACGATACGTGCACCTTTCAAACG 
I156R FOR:GTTTGAAAGGTGCACATCGTGTGATGGATAAAGTC 
 REV:GACTTTATCCATCACACGATGTGCACCTTTCAAAC  
V157R FOR:GAAAGGTGCACATATCCGTATGGATAAAGTCAGC 
 REV:GCTGACTTTATCCATACGGATATGTGCACCTTTC 
T179R FOR:CTGGCGGAAGGCCGTACGATTATTG 
 REV:CAATAATCGTACGGCCTTCCGCCAG 
I181R FOR:GAAGGCACCACGCGTATTGAAAAC 
 REV:GTTTTCAATACGCGTGGTGCCTTC 
E183R FOR:CCACGATTATTCGCAACGCAGCGCGTGAAC 
 REV:GTTCACGCGCTGCGTTGCGAATAATCGTGG 
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Batch affinity fractionation experiments 
Amylose magnetic beads were chosen for batch affinity fractionation 
experiments since the maltose binding protein (MBP) fusion binds specifically to 
amylose resin.  An aliquot (40 l, NEB) of beads was washed with of amylose buffer 
(Chapter III).   A magnet was applied for 1 minute and supernatant was removed.  MBP-
A2 (90 l of 6 M) was incubated for 30 minutes with rolling at 4°C.  Beads were 
washed three times, as above, to remove unbound MBP-A2, vortexing briefly before 
application of magnet and removal of supernatant.  To assess MurA binding to A2, beads 
with MBP-A2 bound were resuspended in buffer containing 100 l of 10 M of MurA 
with the following substrate conditions:  none, 1 mM PEP (Sigma), 1 mM UNAG 
(Sigma), and 1mM PEP/UNAG.  Reactions were incubated at 4°C for 1 hour with 
rolling.  Samples were washed three times and eluted by resuspending beads in 2X 40 l 
of amylose elution buffer (Chapter III).  Samples were analyzed by SDS-PAGE and 
immune-blotting as described previously (Chapter II).  Unbound fractions (supernatant 
of first wash) were analyzed by SDS-PAGE and bound fractions were immune-blotted 
with the -MurA antibody. 
 
Fusion cleavage assay 
Reactions containing 2.5 M of MBP-A2, 5 M MurA under different substrate 
conditions:  none, 1 mM PEP, 1 mM UNAG, 1mM PEP/UNAG, and 1 mM 
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UNAG/Fosfomycin (Sigma), and 10 g of MBP-TEV protease, were processed as 
described in Chapter III.  Fractions were analyzed with SDS-PAGE and immune-
blotting, probed with the -A2 antibody.   
 
MurA bioassay 
Gradient induction of MurA in bacterial lawns of HfrH lacZ::Tn5 harboring 
pZE12-murA, or various alleles (murA*), was generated by plating 200 l of a mid-log 
phase culture in a 0.7 % soft agar overlay supplemented with 2 mM CaCl2 onto LB agar 
plates containing ampicillin and 0 M, 12.5 M, 25 M, 50 M, 100 M or 1 mM of 
IPTG.  An aliquot of cell-free Q lysate (~650 plaque forming units) was included in the 
overlay.  Plates were incubated at 37ºC for 12-16 hrs prior to screening for plaque 
formation (FIG. 47).      
 
Results and Discussion 
Inhibition of purified MurA by Q  
Bernhardt and colleagues (2001) had reported that virion-associated A2 inhibits 
MurA in a crude lysate.  To test whether this inhibition required any other host factor, 
the in vitro assay was repeated with purified MurA and Q particles.  We chose a MurA 
concentration, 400 nM, which reflects the level of MurA in the host cell (Chapter II).  
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FIG. 47.  MurA protection assay induction series. Protection from Q plating 
is observed on induction plates of 100 M IPTG or greater.  Q phage and 
bacteria are included in agar overlay on plates containing increasing amounts 
of IPTG (M): (A) 0, (B) 12.5, (C) 25, (D) 50, (E) 100 and (F) 1000. 
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FIG. 48.  Purified Q inhibits MurA in vitro.  Activity of purified MurA was 
measured in the presence of buffer or purified Q particles.  The rat mutant, 
MurAL138Q, was tested in parallel.  Values are averages of three samples. 
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The results showed that, under these conditions, at the highest possible 
concentration of virions (~700 nM) Q reduced the activity of MurA by 70% when 
compared to a reaction lacking phage particles (FIG. 48).  Under the same conditions, A2 
caused only a marginal reduction in MurAL138Q activity (17%). These results rule out the 
need for other host components in the A2 inhibition of MurA.   
 
The A2 interaction with MurA is conformation-dependent 
Batch affinity fractionation experiments using a purified fusion protein, MBP-A2, 
provide in vitro evidence for a direct interaction between A2 and MurA (FIG. 49A-B).  
Information about the conformational state of MurA required for MBP-A2 association 
was obtained by assaying binding in the presence of various substrates.  MBP-A2 
preferentially bound to both the UNAG-liganded and the tetrahedral intermediate states 
of MurA but not the unliganded or PEP-bound states (FIG. 49A, lanes 2-5), suggesting 
that A2 associates with MurA in a closed conformational state (FIG. 7).  Binding of A2 to 
MurAL138Q was not observed under these conditions (FIG. 49A, lanes 7-10), suggesting 
that the mutation reduces the affinity of A2 for MurA. 
Binding was also analyzed by another method in which cleavage of the fusion 
protein from A2 was performed in the presence of various substrate-induced MurA 
conformations.  A2 cleaved from the MBP fusion protein was insoluble both in the 
absence and presence of unliganded MurA (FIG. 49C, lanes 4-9; FIG. 49D, lanes 2-7).    
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FIG. 49.  A2 binds MurA in a substrate-dependent manner.  (A) MBP-A2 
associates with MurA in a closed conformational state.  Eluates from amylose 
magnetic bead fractionation experiments were Western blotted and probed 
with the α-MurA antibody.  MBP-A2 was incubated with MurA under various 
substrate conditions:  No substrate (-), PEP (P), UNAG (U), and both 
substrates (U/P).  MurAL138Q rat mutant was tested in parallel.  (B) Unbound 
fractions of panel (A) experiments.  (C) Fusion cleavage analysis of A2-MurA 
binding.  MBP-A2 was cleaved with TEV protease in the absence or presence 
of MurA under various substrate conditions (same as in panel A).  Binding was 
assessed as A2 solubility after centrifugation:  Total fraction (T), supernatant 
after centrifugation (S), and pellet fraction (P).  Samples were resolved on 
SDS-PAGE.  MBP-A2 has an apparent MW of 100 kDa.  Cleaved A2 runs at 50 
kDa with the MBP running at the same apparent MW as MurA (~52 kDa).  (D) 
A2 binds MurA liganded to UNAG.  Western blot analysis of fusion cleavage 
assays.  Blots were probed with the α-A2 antibody.  Binding was tested with 
substrate conditions as in panel C.  (E) A2 does not bind the tetrahedral 
intermediate state of MurA.  UNAG and Fosfomycin (U/F) liganded MurA and 
MurAD305A binding and immune-blotting was also performed in parallel as in 
panel D. 
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Addition of PEP to the reaction with MurA did not increase A2 solubility (FIG. 49C, 
lanes 10-12; FIG. 49D, lanes 8-10), but when UNAG was included in the reaction, A2 
remained soluble (FIG. 49C, lanes 13-15; FIG. 49D, lanes 11-13), indicating the 
formation of an A2-MurA complex.  However, in the presence of both substrates, A2 was 
insoluble (FIG. 49C, lanes 16-18; FIG. 49D, lanes 14-16), indicating a preference for 
binding to the UNAG liganded form and not the tetrahedral intermediate state.  This 
result is contradictory to the batch affinity data in which MurA association was observed 
in the presence of both substrates (FIG. 49A, lane 5).  Comparison of the two fractions 
revealed a reduction in the amount of MurA bound in the presence of both substrates 
suggesting that the fraction of MurA bound to A2 could be in the UNAG liganded state, 
rather than tetrahedral intermediate state.  Alternatively, the addition of fosfomycin with 
UNAG, which locks the enzyme into a closed conformational state (FIG. 7), reduced the 
amount of soluble A2 but did not eliminate binding altogether (FIG. 49E, lanes 1-3).     
Dynamics of the catalytic loop upon addition of both substrates might create 
unfavorable conditions for A2 association.  To address this possibility, MurA
D305A was 
purified and fusion cleavage of MBP-A2 was repeated.  MurA
D305A is unable to eliminate 
the product after substrate addition and locks MurA in the tetrahedral intermediate state 
(FIG. 50) (43, 130).  Similarly to the fosfomycin with UNAG bound MurA, a portion of 
A2 remained soluble in the presence of both UNAG and PEP; however, A2 was insoluble 
with the addition of only UNAG (FIG. 49E, lanes 11-16).  The purified D305A protein 
has an increase in absorbance at 260 nm, where UNAG absorbs, compared to WT (data 
not shown) suggesting that the substrates do co-purify with the protein.  Therefore,  
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FIG. 50.  Active site analyses of MurA substrate-dependent conformations.  
(A) MurA bound with UNAG (Han H., unpublished; PDB entry 3KQJ), (B) 
MurA bound with UNAG and Fosfomycin (PDB entry 1UAE) (138), (C) 
MurA tetrahedral intermediate with a fluorinated analog (PDB entry 1A2N) 
(137), and (D) MurA tetrahedral intermediate (D305A mutant, PDB entry 
1Q3G) (43).  Catalytic loop displayed as grey spheres, Arg 397 displayed as 
red spheres, and substrates shown as spheres and colored according to 
elements.  Figures were generated using PyMOL (133). 
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addition of UNAG would have no effect on A2 solubility since the protein already has 
both substrates bound and suggests that A2 does not bind the tetrahedral intermediate 
state.  The partial solubility of A2 in the fraction that included both substrates (FIG. 49E, 
lane 15) was reproducible, possibly indicating that the mutant retains a low level of 
activity, such that A2 is able to bind in the preferred UNAG-liganded state.  When WT 
MurA is added to a reaction with both substrates without prior incubation on ice, a 
fraction of A2 appears in the soluble fraction (data not shown) suggesting that A2 is able 
to bind the UNAG state rather than the tetrahedral intermediate if the enzyme is not 
permitted to equilibrate with both substrates prior to the A2 fusion addition.            
When structures of the active sites and catalytic loop conformations of the 
various MurA-liganded states were viewed, no apparent conformational difference is 
seen between the UNAG and the UNAG/fosfomycin-liganded states (FIG. 50A-B); 
however, a difference between the conformations of the catalytic loop between the 
UNAG/fosfomycin and tetrahedral intermediate states is visible (FIG. 50B-D).  The 
substrates appear to be more accessible to the solvent in the active site of the tetrahedral 
intermediate state than that of UNAG or UNAG/fosfomycin complexes.  Perhaps this 
slight change in the conformation of the catalytic loop with the addition of another 
substrate besides UNAG can explain the differences in the solubility of A2 above.  
Interestingly, A2 was soluble when cleaved from MBP in the presence of 
MurAL138Q liganded with UNAG (FIG. 51).  This was surprising since the batch  
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affinity experiment in which MBP-A2 did not bind MurA
L138Q had higher concentrations 
of protein.  MBP could be causing steric hindrance on A2 association with MurA such 
that an addition of the L138Q substitution reduces the strength of the interaction.  
Alternatively, the bound fraction in the batch affinity experiment was washed three times 
prior to elution; these wash steps reduce the concentration of the protein in solution and 
could cause dissociation of the complex if the mutation has a reduced affinity for A2.  
The notion that reduction in affinity between A2 and the MurA
L138Q mutant is supported 
by the yeast-two-hybrid data which had reduced growth compared to WT (FIG. 52) (89).     
  
FIG. 51.  A2 binds MurA
L138Q.  Fusion cleavage of MBP-A2 was tested in the 
presence of UNAG bound MurA and MurAL138Q.  Solubility of A2 after 
centrifugation:  Total fraction (T), supernatant after centrifugation (S), and 
pellet fraction (P) was assessed by Western blot that was probed with the α-A2 
antibody. 
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FIG. 52.  Yeast-two-hybrid analysis of the A2-MurA interaction.  Data 
reprinted with permission (89).  (A) Yeast strains harboring binding 
partners (A2 and MurA/MurA
L138Q) on selection medium.  (B) Yeast 
strains harboring binding partners on stringent medium conditions 
requiring protein association for growth.  Negative control:  Lam-T pair 
and positive control:  53-T pair  
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FIG. 53.  MurArat alleles protect against A2 at lower inducer concentrations.  
IPTG induction levels that afford cells expressing MurA* variants protection 
from Q infection are depicted by bars.  Rats were considered any allele 
providing protection below the WT level of inducer concentration (100 M) 
(grey bars).  Alleles that protected at inducer concentration levels equivalent to 
or higher than WT are shown as black bars. 
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Identification of a MurA binding surface for A2  
To determine residues involved in the A2 interaction with MurA, arginine-
scanning mutagenesis of residues spatially surrounding the position of the original rat 
mutation, L138Q, was performed, with each allele assessed for its ability to confer 
resistance to Q.  Each murA* allele was expressed from a medium-copy plasmid over a 
range of inducer concentrations, and the level of inducer required to prevent Q plaque-
formation was determined.  Under these conditions, the WT murA allele provides 
protection at 100 M IPTG (FIG. 53 and FIG. 47), whereas the L138Q rat allele 
required only 12.5 M IPTG.  Using these two benchmarks, the new Arg-substituted 
alleles, and a few alleles where parental Arg and Lys residues were changed to Glu or 
Asp, were assayed (FIG. 53).  
The results showed that the mutant collection fell into several distinct classes.  
One class was indistinguishable from WT murA, in providing protection at 100 M 
IPTG (FIG. 53) and were thus considered irrelevant to the A2-MurA interaction.  A 
second class required much higher levels of inducer than the parental allele.  These 
variants accumulated normally in vivo (FIG. 54) but exhibited little to no enzymatic 
activity (data not shown), suggesting improper folding.  A third group of alleles (Y84R, 
A134R, E337R and R340E) showed no protection at low inducer concentrations and 
were inviable when inducer was present at 1 mM IPTG (data not shown), presumably 
due to the accumulation of insoluble material to toxic levels.   
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FIG. 54.  MurA* variant expression test.  TCA precipitated cells expressing 
MurA* variants were run on SDS-PAGE.  Alleles are shown above lanes.  Top 
panel reprinted with permission (89).  Uninduced control (ui) and Luciferase 
control (Luc) 
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FIG. 55.  Rat residues define a Q A2 interaction surface important for 
inhibition of MurA.  (A) Rat residues highlighted on the MurA UNAG-bound 
state (closed conformation, front view) (Han H., unpublished; PDB entry 
3KQJ) defines a continuous surface for A2 interaction.  The structure of (B) 
MurA unliganded (front view) (131) and (C) MurA unliganded (side view) 
disrupts the A2 interaction surface with the conformational change in the 
catalytic loop backbone.  Rat residues depicted as red spheres.  Residues of the 
catalytic loop are shown as grey spheres.  Figures were generated using 
PyMOL (133).  
125 
 
 
A final class of variants were identified that provided resistance at inducer 
concentrations less than 100 M were categorized as rat alleles; this class was 
comprised of 17 allelic substitutions at 15 codons (FIG. 53).  When these mutations were 
mapped onto the UNAG-liganded MurA crystal structure, an apparent A2-interaction 
surface could be visualized (FIG. 55 and FIG. 56).   Residues important for A2 inhibitory 
activity localize at sites surrounding the catalytic loop surface of the enzyme, including 
the catalytic domain, catalytic loop and C-terminal domain (FIG. 55A).  Disruption of 
this interaction surface by conformational changes in backbone of the catalytic loop can 
be observed when the mutations are mapped on the unliganded MurA crystal structure 
(FIG. 55B-C).  This genetic evidence supports the notion that a closed conformation of 
MurA is required for inhibition by A2. 
To determine whether the MurA* variants are not simply complementing the loss 
of the endogenous MurA activity, an additional D305A mutation was introduced to 
inactivate the enzyme (130).  Under these conditions, protection from Q requires that 
each D305A variant titrates out the inhibitory A2 produced during the infection cycle, 
thus sparing the endogenous parental MurA activity.   However, if A2 is unable to 
associate with the mutant protein because of disruption of the A2-MurA binding 
interface, no protection should be observed.  In this experiment, the D305A version of 
the parental MurA provides protection, whereas the D305A version of the canonical rat   
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FIG. 56.  MurA mutant surface maps.  (A) MurA mutational data.  Catalytic 
loop displayed as grey spheres.  Rats are colored red.  Residues providing 
protect ≥ WT are shown in purple (weaker WT induction phenotype is lighter 
purple).  Residues that are non-functional are shown as yellow spheres. (B) 
Differentiation of rat residues.  Basal level protection rats are displayed as red 
spheres.  Medium protecting rats are colored orange.  Low protecting rats are 
shown in yellow.  All residues were mapped onto the MurA UNAG-bound 
state (“closed” conformation, front view) (Han H., unpublished; PDB entry 
3KQJ).  Figures were generated using PyMOL (133). 
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allele does not (TABLE 12).  In this assay, all of the new rat alleles failed to provide 
protection against Q, supporting the notion that these alleles define an A2 binding 
surface.    
When the rat residues are differentiated based upon the level of inducer needed 
to provide protection, (FIG. 53 and FIG. 56) there appears to be a correlation with the 
position of the residue.  The residues with the greatest effect are located at the base of 
the catalytic loop as well as the point where the loop contacts the C-terminal domain.  
This could suggest that dynamics of the catalytic loop play an important role in the 
inhibition process.  However, when the catalytic activity of MurAL138Q was assayed, no 
difference was found between the mutant and WT (FIG. 48).  From this perspective, it is 
more likely that these residues are important contacts for A2 in preventing movement of 
the catalytic loop and blocking substrate accessibility once bound to MurA.  
 
Discussion 
A2-MurA interaction:  Model for inhibition 
The combined results of the enzymatic assays with purified components, binding 
experiments using the MBP-A2 fusion, and yeast-two-hybrid analysis demonstrate that 
the Q A2 maturation protein inhibits MurA by forming a complex that requires no other 
host or viral protein.  This finding is important for several reasons:  (i) it demonstrates   
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TABLE 12.  MurA*D305A Q protection assay. 
Protects 
No plaques 
Does not Protect 
Plaques 
WT (D305A) 
L111R 
S127R 
E130A 
Q131R 
G133R 
T135R 
K137D 
L138P 
E139A 
E139R 
E140R 
G141R 
K152R 
H155R 
V157R 
D159R 
K160R 
V335R 
R391R 
L138Q 
V87R 
K88E 
A119R 
P121R 
V122R 
I126R 
E130R 
I136R 
L138M 
L138R 
V143R 
I156R 
N330R 
F332R 
M333R 
P336R 
M366R 
T368R 
H394R 
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that cellular lysis is not dependent on the participation of host components, (ii) it 
militates against the involvement of viral particles in lysis, and (iii) suggests that 
structural analysis of the A2-MurA complex would be informative for identification of a 
potential peptide-based inhibitor of MurA.   
Regarding the structure, the in vivo protection assays allowed us to characterize a 
potential A2-MurA binding interface.  These genetic results identified residues of 
importance that cover the catalytic loop/cleft and include residues that encompass both 
the catalytic and C-terminal domains of MurA.  The fact that the surface spans the 
catalytic loop/cleft suggests that A2 binds MurA in a closed conformation.  This is 
supported by binding studies where we showed that A2 preferentially associates with 
MurA in the UNAG singly-liganded state.  Moreover, addition of a second substrate 
besides UNAG either severely reduces the ability of A2 to complex with MurA or 
abrogates it altogether under the conditions assayed, suggesting that the catalytic cleft is 
in fact an important contact site for A2.  This binding interface of MurA is dominated by 
regions of negatively charged residues surrounding the rather hydrophobic catalytic loop 
(FIG. 57).  A2 seems to have hydrophobic character, based on its strong tendency to 
aggregate even when fused to highly soluble protein domains, and, in its role as the 
maturation protein, must be able to associate with the viral RNA.  Thus the putative 
MurA binding surface we have described by genetic means has features consistent with 
binding properties of A2. We hypothesize that the reason A2 was able to acquire the role 
as lysis protein in the Q system, in addition to binding the F-pilus, protecting the viral   
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FIG. 57.  The surface of MurA has negatively charged and hydrophobic 
characteristic. (Red) negatively charged residues, (blue) positively charged 
residues, and (white) hydrophobic residues. MurA tetrahedral intermediate 
(PDB entry 1A2N) (137) was used to generate figures with the online server:  
(http://kryptonite.nbcr.net/pdb2pqr/) (36).  (A) surface view (B) transparent 
view 
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RNA, and assembly onto the virion capsid, was due to the hydrophobic and negatively 
charged nature of the MurA surface.      
 
Proteins as inhibitors of enzymes  
Protein inhibitors of enzymes involved in biosynthetic pathways are rare.  One 
inhibitor, E, the lysis protein of ssDNA Microviridae phage X174, targets MraY, an 
enzyme in the cell wall synthesis pathway (14).  It was proposed that upon E binding to 
MraY a conformation change occurs in two transmembrane domains of MraY that in 
turn inactivates the enzyme irrespective of substrate binding (178).  A second inhibitor, 
T7 Lysozyme, binds to the T7 RNA polymerase palm and finger sub-domains and locks 
the protein in a non-processive conformation (68, 176).  This association is independent 
of substrate binding and does not occlude the active site thereby, inhibiting the protein 
indirectly by preventing a conformation change (176).  A2-MurA complex formation on 
the other hand, requires a conformational change of the catalytic loop produced from 
UNAG binding to MurA prior to A2 association.  The presence of an additional substrate 
molecule, such as PEP, prevents this A2-MurA interaction (FIG. 49D, lanes 11-16).  
Therefore, A2 must bind UNAG-liganded MurA over the catalytic loop/cleft and occlude 
PEP from the active site.  Neither T7 lysozyme nor A2 bind their targets directly in the 
active site.  Perhaps evolving the ability to become a competitive inhibitor requires a 
protein to adopt a highly specific tertiary structure which limits the number of roles a 
132 
 
 
protein can fill.  Thus, a form of mixed inhibition is better suited for these proteins to 
maintain additional functions apart from inhibition.     
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CHAPTER V 
BACILLUS SUBTILIS MURAA STRUCTURE AND FUNCTION  
Introduction 
The Gram-negative bacterium E. coli contains only 1 UDP-N-acetylglucosamine 
1-carboxyvinyltransferase, MurA, which is essential for catalysis of precursor subunits 
of peptidoglycan (97).  In contrast, the Gram-positive bacterium Bacillus subtilis (Bs) 
has a homolog, MurAA, which shares 48% identity and 65% similarity to E. coli MurA 
(79).  MurAA catalyzes the same step in the peptidoglycan synthesis pathway and 
complements an E. coli murA knockout (89).  Bs also has paralog of MurAA, MurAB, 
which shares 50% identity and 70% similarity but is unable to complement the loss of 
MurAA.  Perhaps MurAB serves to complement MurAA loss due to Clp-dependent 
proteolysis; the protein has a half-life for the protein of 55 minutes (79) and is degraded 
during stationary phase and MurAB assists in the transition into vegetative growth.  
Alternatively, the turn over number for MurAB catalysis could be too low to compensate 
for the cellular precursor subunit requirement.  
Entry into stationary phase is regulated differently in E. coli.  It was recently 
identified that the enzyme forms a dormant complex with UNAM (FIG. 6), the product 
of MurB, when the ratio of UNAM:UNAG is high (104).  It is not until the intracellular 
concentration of UNAG increases and displaces the UNAM (179) that enzymatic is 
continued.  The complex also forms a covalent adduct between the Cys in the catalytic 
loop and PEP, which may serve to prevent oxidation of the catalytic Cys.  
134 
 
 
It was previously determined that MurAA is able to complement the activity of 
E. coli MurA (89) and was used to aid in expression and purification of toxic A2 
(Chapter II).  Even at low MurAA (plasmid with a pSC101* origin of replication) and 
high A2 (T7 promoter) expression levels, cells were provided protection from lysis (FIG. 
58).  These data suggest that MurAA is a functional enzyme that can complement E. coli 
MurA activity but has intrinsic properties that afford it protection from A2 inhibition.  
This chapter addresses whether an interaction between A2 and MurAA occurs and 
characterizes the differences between MurAA and E. coli MurA that provides protection 
from A2 inhibitory activity. 
 
Material and Methods 
Bacterial strains and growth conditions   
The Escherichia coli strains used in this study:  ER2738, HfrH, HfrH lacZ::Tn5, 
HfrH murA::kan pZE12-murABs, and BL21(DE3) are previously described (Chapter II) 
(153).  Standard molecular biology techniques were performed as described elsewhere 
(129).  Bacterial growth conditions were described in Chapter II. 
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FIG. 58.  The A2
1-189 protein inhibits Bs MurAA.  BL21(DE3) pLysS pZS*21-
murA
Bs lysis was observed with: pET-A2 (squares:  uninduced, white; induced, 
black) or pET-A2-190 (circles:  uninduced, white; induced, red).  Samples were 
induced with 1 mM IPTG (final) at Time = 0’. 
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Plasmid construction   
Plasmid construction for pZE12-luc was previously published (96).  Construction 
of pZE12-A2, pZE12-A2L28P, pZE12-A2D52N, pZE12-A2E125G, pZE12-murA, and 
pZE12-murABs were described in Chapter II.  pZE12-murABsD306A was generated by 
site-directed mutagenesis with the following primers:  BsMurA-D306A-For 
CCGGGCTTCCCGACTGCTATGCAGTCACAAATG and BsMurA-D306A-Rev 
CATTTGTGACTGCATAGCAGTCGGGAAGCCCGG.  An oligo-histidine tag 
(G2H6G2) was adjoined to the C-terminus of murA
Bs by site-directed mutagenesis (V. 
Kuznetsov) for purification purposes.  All in vitro analyses uses the oligo-histidine-
tagged MurAA.  pLysS and pET-11a were obtained from Novagen.  pET-A2 and pET-
A2-190 were constructed previously (89).  To generate pZS*21-murA
Bs, pZA31-murABs 
(89) was digested with AvrII and XhoI and ligated into pZS*24 (96), similarly digested.  
The pZS*21-murABs contains the PLtet0-1 promoter that is constitutively expressed in a 
tetR
- background. 
 
Protein expression and characterization   
MurAA expression and purification were performed as described in Chapter II 
for E. coli MurA.  MBP-A2 was purified with amylose resin as described in Chapter III.  
Fusion cleavage and batch affinity fractionation experiments were performed as 
described previously (Chapter III and Chapter IV, respectively).  SDS-PAGE and 
immune-blotting was performed as described (Chapter II) with the following 
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modifications:  1:3,000 dilution of -His (Amersham) and 1;10,000 goat-anti-mouse 2° 
antibody (Pierce) were used for immune-blotting of MurAA. 
To test activity of the MurAA, 2.5 X 108 cells were centrifuged at 18,000 xg for 
5 min at 22°C.  The cell pellet was resuspended in 1 ml LB with 0.5% toluene and 
incubated at 37°C for 5 minutes.  Cells were pelleted as above, resuspended in 1 ml of 
buffer (0.1 M Tris-HCl [pH 8], 0.5% toluene) and incubated as stated above.  Cells were 
pelleted a third time and resuspended in 100 l of buffer (0.1 M Tris-HCl [pH 8]).  Five 
l of toluenized cells was assayed for MurA activity as described previously (97).   
 
Phage purification and plating   
Purification of cell-free phage lysate and plating methods were performed as 
previously described (Chapter II). 
 
Results and Discussion 
MurAAD306A mutation does not protect in bioassay 
An interaction between MurA and A2 was previously demonstrated with plasmid 
induced E. coli MurAD305A during a Q infection (see Chapter IV and FIG. 49D).  The 
D305A mutant is catalytically inactive and affords the cell protection from lysis by 
binding and titrating A2.  To determine whether MurAA interacts with A2 in vivo, the   
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equivalent to the D305A (D306A) change was incorporated into the sequence of MurAA 
and the Q plating bioassay was performed as in Chapter IV.  The results were 
unambiguous.  At uninduced, basal level of expression, the catalytically active MurAA, 
but not the catalytically inactive MurAAD306A, provided protection from Q lysis (FIG. 
59).  Moreover, even induction of the mutant did not provide protect from Q plating 
(FIG. 59G).  This plating phenotype is similar to that seen by E. coli MurAL138Q (FIG. 
59C & E) where incorporation of the D305A double mutation does not protect the   
FIG. 59.  Bs MurAAD306A does not protect during a Q infection.  Q phage 
was plated on HfrH lacZ::Tn5 lawn harboring the following plasmids:  (A) 
pZE12-luc, (B) pZE12-murA, (C) pZE12-murAL138Q, (D) pZE12-murAD305A, 
(E) pZE12-murAL138Q,D305A, (F) pZE12-murAA, and (G) pZE12-murAAD306A.  
Lawns were prepared with and without 1 mM of IPTG for protein expression. 
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FIG. 60. Bs MurAAD306A is expressed.  Samples were resolved on SDS-PAGE.  
E. coli MurA has an apparent molecular mass of 50 kDa and MurAA, 52 kDa.  
Lanes:  (1) Molecular mass standard, (2) Luciferase control, (3) E. coli MurA, 
(4) E. coli MurAD305A, (5)  MurAA, and (6) MurAAD306A     
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cells against a Q infection, suggesting that this mutation prevents A2 from associating.   
The phenotype could also be a result from expression of misfolded protein, such 
that A2 binds the endogenous MurA and induces cellular lysis.  To address this 
possibility, protein activity, accumulation, and solubility were assessed.  Both the 
MurAD305A and the MurAAD306A mutants accumulated to similar levels as their 
prospective WT proteins (FIG. 60), and as expected, neither had detectable activity 
(FIG. 61).  However, when the solubility of the proteins were analyzed the MurAA 
mutant showed substantial precipitation of the protein, with ~ 70% in the pellet fraction 
(FIG. 62); whereas, the E. coli mutant had about 50% in the pellet (130).  Binding of   
FIG. 61.  Bs MurAAD306A mutant is nonfunctional.  E. coli toluenized cells 
expressing MurAD305A have no activity compared to cells expressing MurA and 
the Luciferase control (panel A).  Cells expressing MurAAD306A similarly do 
not have any activity (panel B). 
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FIG. 62. Bs MurAAD306A has reduced solubility.  Cellular lysate prior to 
centrifugation, Total (T), and fractions after centrifugation, Supernatant (S) 
and Pellet (P), were resolved on SDS-PAGE.  MurAA has an apparent 
molecular mass of 52 kDa. 
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FIG. 63.  MurAA protects during a Q infection. (A) HfrH overlays and (B) 
HfrH murA::kan pZE12-murABs overlays:  without (left) and with (right) 1 mM 
IPTG inducer, spotted with serial dilutions of phage, labeled above. 
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purified MurAD05A to A2 was previously demonstrated (Chapter IV) even though a high 
distribution of insoluble protein is obtained in the pellet fraction during purification.  
Therefore, the 30% of soluble protein could be properly folded, but the only measure for 
proper folding of the inactive enzyme is the ability to bind A2.  Since the ability of 
MurAA to bind A2 is not known, we cannot determine from these experiments whether 
the mutant is misfolded and further characterization was abandoned. 
  
MurAA is sensitive to Q A2
 por but not Q 
To further address whether MurAA is able to bind A2 in vivo, Q was plated on a 
lawn of E. coli cells deleted for the chromosomal copy of the murA gene and carrying a 
complementing murAA gene on a plasmid.  Even the basal level of MurAA was able to 
inhibit Q plating (FIG. 63B) suggesting that A2 does not inhibit MurAA.  However, Q 
A2 
por mutants exhibited low but detectable efficiencies of plating on these lawns (FIG. 
63A).   The por phenotype is due, at least in part, to an upregulation of A2 expression 
during infection (Chapter II, FIG. 14).  Thus, these plating results indicate that A2 can 
bind and inhibit MurAA if expressed at enhanced levels.  This interpretation is 
consistent with the ability of A2
 por alleles to support plaque formation on the E. coli rat 
mutants carrying the original L138Q change in MurA.   
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MurAA binding by A2 cannot be detected in vitro 
Binding and fusion-cleavage studies with a purified fusion of A2, MBP-A2, 
allowed characterization of the E. coli MurA-A2 interaction (see Chapter IV).  Therefore, 
these studies were repeated with MBP-A2 and purified MurAA (FIG. 64).  Batch affinity 
fractionation experiments revealed that MurAA did not bind to A2 under any condition 
tested (FIG. 65); however, there is a high background from MBP-A2 degradation 
products, at least in part because both MBP-A2 and MurAA have a His-tag,   
FIG. 64.  Purification of MurAA.  Purity of MurAA was verified by resolving 
on SDS-PAGE.  Lanes: (S) Supernatant of clarified lysate, (P) Pellet of 
clarified lysate, (FT) Column flow-through, (W) Column washes, and (E) 
Eluate fractions 
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FIG. 65.  Batch affinity fractionation of MBP-A2 and MurAA.  Unbound 
fractions were resolved on SDS-PAGE and Bound fractions were immune-
blotted with an -His antibody.  MurAA runs at about 52 kDa and MBP-A2 at 
approximately 98 kDa.  Apparent protein laddering in Bound fractions is from 
MBP-A2 degradation products. 
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FIG. 66.  Fusion cleavage analysis of MBP-A2 with MurAA.  Fractions of 
MBP-A2 cleavage prior to centrifugation, Total (T), or after centrifugation, 
Supernatant (S) and Pellet (P), were immune-blotted with an -A2 antibody.  
Uncleaved MBP-A2 has an apparent molecular mass of 98 kDa and cleaved A2, 
~ 50 kDa.   
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the epitope used for detection.  Less ambiguous results were obtained with the fusion 
cleavage protocol.  For all MurAA-liganded states tested, A2 appears to be 
predominantly in the pellet fraction, with only a small fraction in the supernatant fraction 
(FIG. 66, lanes 5-16).  This was not observed with the MBP-A2-only control (FIG. 66, 
lane 2-4), which showed all of the A2 protein in the insoluble fraction.  The results were 
reminiscent of the results with the E. coli MurA-UNAG/fosfomycin- complex (FIG. 49) 
which exhibited reduced binding compared to the UNAG only state, presumably due to 
small differences in the loop structure (FIG. 50).  One possibility to explain these results 
is that the protein was co-purified with UNAM and PEP bound, which induces a closed 
conformation of MurAA (87) (FIG. 67).  A concentration of 1 mM UNAG can displace 
UNAM (179), and when included in the reactions there should be differential binding of 
A2 in the 2 reactions that contained UNAG, as seen previously with E. coli MurA (see 
Chapter IV, FIG. 49); however, this was not observed for any of the samples.  It is more 
likely that MurAA exhibits weak binding to A2 that is not dependent on a 
conformational change for association. 
 
A2 truncation effects on MurAA inhibition 
Previously it was demonstrated that expression of MurAA during a Q infection 
protects against cellular lysis (89).  This protection was utilized for co-expression with 
A2 fusion constructs to counteract the toxic effect of the lysis protein (Chapter III).    
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FIG. 67.  Active site comparison of E. coli MurA and Bs MurAA.  (A) 
Enterobacter cloacae MurA bound with UNAM and PEP (PDB entry 3SU9), 
(B) E. coli MurA bound with UNAG (PDB entry 3KQJ), (C) E. coli MurA 
tetrahedral intermediate (PDB entry 1A2N), and (D) MurAA bound with 
UNAM (V. Kuznetsov, unpublished).  Catalytic loop displayed as grey 
spheres, Arg 397 (E. coli) and Arg 398 (Bs) displayed as red spheres, and 
substrates shown as spheres and colored according to elements (E. coli MurA, 
not displayed for MurAA).   
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FIG. 68.  E. coli MurA and Bs MurAA alignment.  Residues important for an 
A2 interaction are labeled with asterisks.  Conserved residues (red) and non-
conserved and semi-conserved residues (pink) 
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However, analysis of MurAA co-expression with the A2
1-189 truncation protein revealed 
that the protein is still lytic in cells that are expressing low levels of MurAA (FIG. 58).  
This lytic activity was not observed with the full length A2.  Perhaps the tertiary 
structure of the full length A2 limits the ability of the protein to complex with MurAA.  
This notion is supported by the fact that two other truncation proteins, A2
1-338 and A2
1-283 
(FIG. 45) are, although stable, soluble proteins in vivo, are both non-lytic, indicating that 
the C-terminal segment of A2 contains a domain that can interfere with MurA binding. 
 
Analysis of the MurAA surface 
The Alloleviviridae exclusively infect Gram-negative hosts, so it is not surprising 
that A2 is not able to bind and inhibit MurAA.  An alignment of the MurAA and E. coli 
MurA primary structures showed 48% identity (FIG. 68).  Comparison of the residues 
that were determined to be important in the E. coli MurA interaction with A2 to those of 
MurAA revealed that 6 out of the 15 residues were not conserved; out of the 6, 3 were 
residues that were semi-conserved.  The position of the non-conserved residues was at 
the base of the loop and at positions close to where the loop contacts the C-terminal 
domain (FIG. 69).  These positions were determined to be important contacts for A2 to 
associate with MurA and inhibit the activity of the enzyme (Chapter IV).  Analysis of 
the residues positions revealed that 2 of the 3 (E337 and A367) that in positions on E. 
coli MurA (336 and 368) had the weakest protection phenotype against a Q infection 
(see Chapter IV FIG. 53).  The third difference is a Ser substitution at position 121,   
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FIG. 69.  Comparison of A2 interaction surface between E. coli MurA and Bs 
MurAA.  (A) E. coli MurA (PDB entry 3KQJ) and (B) MurAA (V. Kuznetsov, 
unpublished), and Residues of the A2 interaction surface are depicted as red 
spheres.  The catalytic loop is shown as grey spheres.  (C) MurAA with 
differentiation of residues based on conservation:  red (conserved), orange 
(semi-conserved), and yellow (non-conserved). 
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which aligns to E. coli MurA position 119; this position provided better protection 
against a Q infection than positions 336 and 368 of E. coli MurA.  Any 3 of these 
substitutions would likely be sufficient to provide MurAA protection from A2 inhibition.  
It would be interesting to see if conversion of these residues to the corresponding 
residues in E. coli MurA would confer some ability for A2 to inhibit the enzyme.  An 
additional non-conserved residue at position 118, an adjacent residue to the catalytic Cys 
within the loop, which was not subjected to extensive mutagenesis in E. coli MurA, 
could also potentially affect the ability of A2 to bind MurAA (FIG. 68). 
Another factor that influences the ability of A2 to bind and inhibit MurA is the 
conformation of the catalytic loop.  It was determined in the previous chapter that small 
conformational difference in the loop associated with differential substrate binding 
affected the degree of A2 association with MurA.  Comparison of the catalytic 
clefts/loops of UNAM-liganded MurAA and several MurA structures that are in a closed 
conformation revealed that UNAM-liganded MurAA has a more solvent-accessible 
active site, similar to the tetrahedral intermediate of E. coli MurA (FIG. 67).  It was 
previously shown that A2 binds the UNAG-liganded state of MurA and not the 
tetrahedral intermediate (Chapter IV, FIG. 49).  Until structural data for other liganded 
states of MurAA is available, loop conformation cannot be considered as a major factor 
to explain why A2 has a reduced affinity for MurAA.  
Analysis of the electrostatic surface density of the two proteins revealed a large 
difference in the C-terminal domain just above the catalytic loop.  MurAA had a 
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considerable region of negative charge in contrast to MurA, which had more 
hydrophobic characteristic (FIG. 70).  The residues on the C-terminal domain contacted 
by the loop were determined to be important for A2 inhibition of MurA (Chapter IV, 
FIG. 56B).  Unfortunately, a more complete analysis of the A2 interaction surface with 
E. coli MurA in this region could not be performed, because mutations in this region 
inactivate the enzyme.  Therefore, interaction with A2 in this domain cannot be 
excluded.  Nevertheless, the striking difference in the charge density of this region in 
MurAA compared to E. coli MurA, must be considered as a dominant factor in the lack 
of the affinity of A2 for MurAA. 
 
Discussion 
In vivo titration assays and in vitro binding studies have demonstrated that, 
despite the strong similarity between the crystal structures of MurA and MurAA, A2 
binding and/or inhibition of MurAA is severely compromised  The defect in binding to 
MurAA could be due to several differences in the MurA residues shown to be important 
for A2 binding, to differences in surface charge, or in the structure of the catalytic loop in 
this area  Nevertheless, the Q A2
 por mutants can make plaques at a low but detectable 
efficiency  on an E. coli host with murAA substituted for murA.  It is unclear whether this 
is due to the increased level of A2 in por infections or to the particular aa substitutions  
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FIG. 70. Electrostatic density map comparison of Bs MurAA and E. coli 
MurA.  Electrostatic density maps were generated for Bs MurAA liganded 
with UNAM (V. Kuznetsov, unpublished) (A-B) and E. coli MurA tetrahedral 
intermediate (PDB entry 1A2N) (C-D).  Region of large charge difference on 
the C-terminal domain is highlighted by black oval.  Figures generated with the 
online server:  (http://kryptonite.nbcr.net/pdb2pqr/) (36).    
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in the por alleles, or both.  A plasmid-based expression system for both A2 and MurAA 
with the endogenous E. coli murA knocked out should be able to rule out the effects of 
A2
 por over-expression by normalizing the amount of protein expressed.  Binding studies 
with A2 
por fusion proteins could also provide a way of determining the effect from the aa 
substitutions. 
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CHAPTER VI 
SUMMARY AND FUTURE DIRECTIONS 
Overview 
Since the extensive studies on ssRNA phage replication and gene expression 
during the 1960s, the infection cycle of these paradigm phages has attracted little 
attention.  In particular, since the identification of A2 as the lysis protein in 1983 (72, 
169), there has been nothing published regarding the lytic mechanism except the 
identification of MurA as the host protein targeted by A2 (16).  This dissertation has 
made advancements in this area by characterizing the regulation of A2 expression an 
activity during an infection cycle and the mechanism of MurA inhibition through several 
biochemical and genetic studies.   
 
Model for A2 Regulation During a Q Infection  
We have demonstrated that association of particle-mounted A2 with MurA in 
vitro resulted in virion inactivation with a concomitant release of viral RNA from the 
particles (FIG. 9).  This finding ruled out virion-associated A2 as the inhibitory form of 
A2.  Moreover, titration experiments of plasmid-induced A2 revealed that the amount of 
A2 required to induce lysis is roughly equivalent to the cellular MurA levels (TABLE 6), 
which suggests that once the amount of A2 accumulates to an equimolar amount the cell 
is committed to lysis.  Quantitative analysis of the infection cycle showed that A2 
accumulates to equivalent levels of MurA by 30 minutes after infection (TABLE 7),   
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FIG. 71.  Model for Q lysis.  The Q infection cycle consists of several 
stages:  (1) adsorption to the F-pilus, (2) injection of the A2 and the viral RNA 
into the host cell, (3) synthesis of precursors for progeny virion particles, (4) 
morphogenesis of particles and inhibition of MurA by A2, (5) cell wall 
synthesis inhibition ~60’ after infection, and (6) release of particles at 80’. 
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but lysis is not observed for another 50 minutes (FIG. 14).  The delay in lysis was 
considered to be provided by an unknown “buffer” for A2, i.e., a component that binds 
A2 and protects the endogenous MurA.  Insight into this buffering capacity was obtained 
by analysis of Qpor mutant infections, which revealed an upregulation in the amount of 
A2 earlier in infection, resulting in an earlier lysis phenotype (FIG. 14).  These data are 
interpreted as showing the saturation of the A2 buffering capacity of the system early in 
infection.  Presumably the buffering agent is a viral component that accumulates 
simultaneously with A2.  A clue about the identity of the buffering agent was obtained 
from the observation that ejected RNA from virions protects particles from inactivation 
by MurA, which suggests that A2 is occluded from MurA association by viral RNA.   
We have proposed a model (FIG. 71) in which newly translated A2 binds to the 
viral RNA and by doing so, is sequestered from association with MurA.  Lysis timing in 
this model is linked to the level of free A2 in the system.  Accumulation of free A2 would 
occur by one or both of two means:  (i) displacement of the RNA-bound A2 as viral 
RNA is packaged during morphogenesis or (ii) accumulation of free A2 that exceeds the 
available binding sites of viral RNA during replication.  We cannot distinguish 
rigorously between the two models with the techniques used in this work, but analysis of 
the Qpor data supports the latter model (FIG. 72).  In Qpor infections the point at 
which MurA is inhibited is shortly after translation of A2 begins, ~ 10-15 minutes after 
injection since there is a 20 minute delay from the point at which MurA is inhibited to   
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FIG. 72.  Model for Q  por lysis.  The Q  por infection cycle consists of several 
stages:  (1) adsorption to the F-pilus, (2) injection of A2 and the viral RNA into 
the host cell, (3) synthesis of precursors for progeny virion particles and 
inhibition of MurA by A2, (4) morphogenesis of particles, (5) cell wall 
synthesis inhibition ~10-15’ after infection, and (6) release of particles at 30-
45’.  
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cellular lysis (16).  This is when replication begins and is too early in the infection for 
sufficient particle accumulation to account for the hundreds of molecules needed for 
MurA inhibition. We have interpreted the early lysis phenotype of the por mutants as 
being due to over-production of A2, due to disruption of inhibitory RNA structures that 
occlude the ribosome binding site of the A2 gene.  Nevertheless, it has to be noted that 
only non-synonymous mutations were obtained in the selection for the por mutants 
(TABLE 8).  If upregulation in the translational rate of the A2 gene was the only 
requirement for the plating of Qpor on the rat strain, then synonymous mutants that 
disrupt the secondary structures should also have been isolated.  It is thus conceivable 
that the missense change associated with each por allele, and the consequent potential 
alteration of binding to MurA, also contributes to the por phenotype.  It is also possible 
that the mutations, either at the RNA or aa level, reduce the ability of A2 to bind the viral 
RNA, which would reduce the amount of A2 assembled onto particles and increase the 
pool of free A2.  Alternatively, both the 5’ and the 3’-ends of the viral RNA are 
identified as A2 binding sites (136).  Perhaps the por mutations, which cluster in the 5’-
end, reduce the ability of A2 to bind this region but not the 3’-end, so A2 has a reduced 
number of binding sites on the RNA but can still assemble onto particles.  
 
Characterization of A2 
por Mutants  
Many questions have been raised about why por mutants produce an earlier lysis 
phenotype.  Por mutant A2 proteins need to be purified as soluble fusion proteins and 
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characterized with in vitro binding to MurA and Bs MurAA, in comparison to the WT 
A2.  RNA binding also needs to be tested with these mutants.  This is more challenging 
because of two factors:  (i) the fusion proteins appear to co-purify with RNA (Chapter 
III) and (ii) degradation of the protein occurs during the purification process (Chapter 
III).  Use of a synthetic A2 gene designed to have minimal RNA secondary structure 
could alleviate the problem with co-purification of RNA.  Initial attempts to clone a 
synthetic A2 gene have resulted in frameshift mutations that produce inactive protein 
products (B.C. Bundy, unpublished data), which suggests that basal level of transcription 
during cloning is enough to produce sufficient A2 to induce cellular lysis.  A nonsense 
mutation could be engineered into the first part of the gene to correct the problem, so 
that construction of the synthetic clone could be done in a non-suppressing background 
where escape synthesis of the toxic A2 protein could not occur.  Expression of the 
protein in vitro could be also be a solution to the protease degradation issue (141).   
 
Mechanism of MurA Inhibition 
We have determined from in vitro binding studies with a soluble A2 fusion 
hybrid that A2 preferentially binds to the UNAG bound state of MurA.  Under the 
conditions assayed, A2 had a weakened affinity for the UNAG/fosfomycin complex, and 
did not display binding to the tetrahedral intermediate (FIG. 49).  From crystal structure 
analyses, only minor differences in the loop are seen in the active site pocket (FIG. 50), 
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with the tetrahedral intermediate state exhibiting the largest difference suggesting that 
the loop conformation plays an important role in A2 inhibition of MurA.   
 
Characterization of A2 binding to a dormant complex of MurA 
A recent publication determined that MurA is bound to UNAM and PEP when 
the ratio of UNAM:UNAG is high in the cell (179).  This dormant complex adopts a 
closed conformation very similar to the UNAG-liganded state; perhaps this is the state in 
which A2 binds during an infection.  Binding to the UNAM/PEP liganded state needs to 
be tested to determine whether A2 associates with this dormant state of MurA.  
Purification of MurA excluding the ammonium sulfate precipitation step (Chapter II) 
will provide protein with UNAM and PEP bound. 
 
Probing the A2 Lytic Domain 
Previous analysis of the lytic domain of A2 revealed that the N-terminal 179 
residues of A2 still retain lytic function but the next largest fragment, 1-171, did not 
(FIG. 45) (89).  Secondary structural analysis of A2 predicted that this domain is 
comprised of several beta sheets that are sandwiched between alpha helices (FIG. 44).  
Deletion of the extreme N-terminal helix or truncation of 5 residues of a predicted helix 
that spans from residues 147-176 inactivates A2 (FIG. 45).  We concluded that perhaps 
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these helices act as a scaffold for beta sheet assembly and that this beta sheet domain is 
what comprises the lytic activity of A2.   
 
Characterization of the A2 lytic domain 
Truncation analyses of the first half of A2 support the hypothesis that loss of lytic 
activity by several truncations is due to deletion of alpha helices that surround a beta 
sheet domain.  Mutational analyses of conserved residues within the predicted beta 
sheets in the N-terminal half of A2 need to be performed in an effort to identify the lytic 
domain.   
Crystallization efforts with purified A2 have not been possible up to this point, 
due to the poor solubility of the protein.  A small fraction of the purified, full length 
fusion protein of A2 has degradation of the C-terminal end.  This domain is likely 
sequestered upon virion particle assembly, which is not normally exposed to cellular 
proteases.  The use of lytic A2 C-terminal truncations would alleviate this problem.  The 
A2
1-189 protein also has increased solubility compared to the full length protein (FIG. 40), 
although it still precipitated upon concentration.  Future efforts may focus on using the 
truncation in complex with MurA.  In addition, adding soluble N-terminal domains as 
extensions to the lytic truncation protein may also increase solubility.  There are 
examples of protein fusion crystallization, especially if the linker between the two 
proteins is short (157).   
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Lysis Inhibition of Q (LIN) 
We have shown that an infection of Q at high input MOI produces an LIN state 
(FIG. 22), defined as a state in which lysis protein expression does not result in lysis.  
The accumulation of the lysis protein was not perturbed between the different LIN-
states; thereby, arguing against overall suppression of viral replication.  This LIN state 
was previously noted by Ellis and colleagues for an MS2-like phage, R17 (42); however, 
no further characterization of this phenomenon has been reported.  The fact that both 
Alloleviviruses and Leviviruses experience a similar LIN-induced state despite using 
completely different lysis mechanisms suggests that LIN is imposed by something that is 
common to the infection of both of these phages, when high MOI is used. 
Several issues need to be addressed in order to characterize the LIN state of 
ssRNA phage.  First, in the Levivirus system, the MS2 LIN state must be experimentally 
verified and it must be determined whether L accumulation is normal under LIN 
conditions.  In view of the fact that L lysis does not require cell division, a division-
independent model for the LIN state that is shared between the Alloleviviruses and 
Leviviruses must be proposed.  In fact, it is not known why inhibition of cell wall 
synthesis by A2 or by cell-wall specific antibiotics causes lysis.  It is presumed that 
murein biosynthesis necessarily couples cell wall degradation with biosynthesis, to allow 
for incorporation of new polysaccharide strands; however, failure to incorporate the new 
NAM-NAG disaccharide subunits does not block the degradation process.   Based on 
this operational analysis, one could speculate that the LIN process blocks the 
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degradation associated with murein biosynthesis.  As noted above, it is not known how L 
causes cell wall degradation.  However, the proteins responsible for degradation of 
murein when biosynthesis is inhibited might be the same as the muralytic proteins that 
appear to be activated by L.  If so, then the LIN state might simply reflect the inhibition 
of these muralytic activities.  There are a few candidates for the MOI-dependent LIN 
effector:  the viral Coat, Replicase, or the RNA itself.  Measurement of all viral 
components during an infection of under the LIN and non-LIN states will help clarify 
what is perturbing lysis.  The rat strain could be used for quantification since this strain 
does not lyse when infected with Q WT.  Alternatively, enrichment for phages that are 
able to overcome the LIN lysis block could provide insight into the mechanism of LIN 
regulation.    
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